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Abstract
There is broad agreement that medicine ought to be ‘evidence based’ and ‘person-
alized’ and that data should play a large role in achieving both these goals. But
the path from data to improved medical decision making is not clear. This thesis
presents three methods that hopefully help in small ways to clear the path.
Personalized medicine depends almost entirely on understanding variation in treat-
ment effect. Chapter 1 describes latent class mixture models for treatment effect
heterogeneity that distinguish between continuous and discrete heterogeneity, use
hierarchical shrinkage priors to mitigate overfitting and multiple comparisons con-
cerns, and employ flexible error distributions to improve robustness. We apply
different versions of these models to reanalyze a clinical trial comparing HIV treat-
ments and a natural experiment on the effect of Medicaid on emergency department
utilization.
Medical decisions often depend on observational studies performed on large longi-
tudinal health insurance claims databases. These studies usually claim to identify
a causal effect, but empirical evaluations have demonstrated that standard meth-
ods for causal discovery perform poorly in this context, most likely in large part
due to the presence of unobserved confounding. Chapter 2 proposes an algorithm
called Ensembles of Granger Graphs (EGG) that does not rely on the assumption
that unobserved confounding is absent. In a simulation and experiments on a real
claims database, EGG is robust to confounding, has high positive predictive value,
and has high power to detect strong causal effects.
While decision making inherently involves causal inference, purely predictive mod-
els aid many medical decisions in practice. Predictions from health histories are
challenging because the space of possible predictors is so vast. Not only are there
thousands of health events to consider, but also their temporal interactions. In
Chapter 3, we adapt a method originally developed for speech recognition that
greedily constructs informative labeled graphs representing temporal relations be-
tween multiple health events at the nodes of randomized decision trees. We use
this method to predict strokes in patients with atrial fibrillation using data from
a Medicaid claims database.
I hope the ideas illustrated in these three projects inspire work that someday gen-
uinely improves healthcare. I also include a short ‘bonus’ chapter (based mostly
on the prior work of Li Ye, a former student of my advisor) on an improved esti-
mate of effective sample size in importance sampling. This chapter is not directly
related to medicine, but finds a home in this thesis nonetheless.
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Chapter 1
Latent Class Mixture Models of
Treatment Effect Heterogeneity
1.1 Introduction
In randomized experiments, it is often of interest to characterize treatment effect
heterogeneity in terms of baseline covariates. Usually, the aim is to identify sub-
populations likely to have particularly positive or negative (or neutral) responses to
treatment. The process of searching for such subpopulations after the completion
of an experiment (without pre-specifying which subpopulations will be considered
as candidates) is called ‘post hoc subgroup analysis’. It is a controversial practice.
Concerns about data dredging and multiple comparisons (Rothwell, 2005) have led
many authors to advise against reporting results from post hoc subgroup analyses
at all. However, it is our view that post hoc analyses can produce informative
insights that would be unlikely to arise from limited pre-registered comparisons.
Here we illustrate an approach in which identification of special subgroups is one
byproduct of fully modeling treatment effect heterogeneity more generally. By
placing shrinkage priors on relevant parameters and applying cross validation based
1
tools for model evaluation and comparison, we minimize data dredging concerns
and provide a mechanism for gauging confidence in the substantive implications
of model results.
Employing parametric probability models of heterogeneity brings certain auto-
matic advantages. The parameter estimates have interpretable implications about
the shape of heterogeneity, and models provide estimates of uncertainty about
those parameters. Models also provide estimates of treatment effects for sub-
populations and corresponding uncertainty estimates. And Bayesian models in
particular allow us to place hierarchical shrinkage priors on relevant parameters to
avoid overfitting/data dredging (Gelman et al., 2012). These are obvious features
of parametric probability models and are only worth mentioning because many
methods for subgroup analysis are nonparametric or not model based and do not
share these features.
Of course, any model is bound to be misspecified, and the advantages described
above only apply insofar as the chosen model is a good approximation to reality.
We choose a relatively flexible class of models to improve the chances that some
model in the class approximates reality well. We employ Leave One Out Cross
Validation (LOO-CV) techniques for model comparison and evaluation (Gelfand,
1996; Vehtari and Lumpenin, 2001). For both prediction and inference we pre-
fer models with better LOO-CV estimated expected utility, where a good choice
for utility in this context is posterior predictive density. We estimate uncertainty
about the expected utility of each candidate model and adjust our degree of belief
in each model’s implications accordingly. If multiple models could plausibly have
2
the best true expected utility, we do not draw firm conclusions about aspects of
heterogeneity on which those models disagree. If one model is clearly superior to
the rest and appears to fit adequately based on posterior predictive checks (Gel-
man et al., 1996), then we would be fairly confident in its implications.
Specifically, we propose to model treatment effect heterogeneity using regular-
ized Bayesian latent class mixture models with treatment interaction terms and
flexible error distributions. Such models are particularly well suited to illuminate
the shape of heterogeneity. The treatment interaction terms capture ‘continuous
heterogeneity’ while the latent class components capture ‘discrete heterogeneity.’
By continuous heterogeneity we mean variation in subjects’ individual treatment
effects that is well approximated by a smooth function of underlying covariates.
Discrete heterogeneity refers to variation in subjects’ individual treatment effects
that is associated with latent class membership, where latent class membership
may in turn be associated with baseline covariates. Discrete heterogeneity is likely
to be present if a treatment works through unobserved causal pathways that may
be discretely open or closed. For example, suppose a drug works better in peo-
ple with a specific phenotype for some protein receptor, but the presence of that
phenotype is not recorded as a baseline covariate in a clinical trial evaluating the
drug. Further, suppose that a recorded baseline covariate (say, weight) is associ-
ated with the presence of the beneficial phenotype. Then treatment effect variation
as a function of weight will be better approximated by a latent class model with
weight as a predictor of latent class membership than by any smooth function of
weight alone. It can sometimes be important to understand which type of hetero-
geneity is present.
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Despite our approach being a fairly straightforward application of Bayesian latent
class mixture models and existing model comparison and evaluation techniques,
we have not seen it in the subgroup analysis literature. Further, our approach
offers a different combination of strengths (and weaknesses) from those methods
we have seen.
One general tactic in the literature is to use nonparametric machine learning algo-
rithms (often based on trees) to predict counterfactual outcomes of future subjects
under treatment and control. Examples of works in this vein include (Kang et al,
2012; Foster et al., 2010; Su et al, 2009; and others). These methods likely have the
edge over ours when it comes to predictive accuracy and flexibility. Some of them
also use cross validation to effectively mitigate multiple comparisons concerns.
However, many do not provide estimates of uncertainty about their predictions
and usually do not characterize the shape of heterogeneity interpretably. (Athey
and Imbens, 2015) recently proposed a machine learning approach that produces
valid standard errors for causal effect estimates within nodes of a tree fit to a
holdout validation set. Of course, holdout validation sets may not be practical for
smaller experiments.
A closely related line of work directly learns optimal treatment assignment rules
without first estimating counterfactual outcome response surfaces (Qian and Mur-
phy, 2011; Zhang et al, 2012; Zhao et al, 2012). These methods are not interested
in learning about heterogeneity, just assigning the best treatment to each subject.
They have similar strengths and weaknesses relative to our method as the machine
4
learning approaches described above.
(Imai and Ratkovic, 2012) employ a linear SVM model with interaction terms
to model heterogeneity. The output of their model is interpretable, and they place
shrinkage penalties on the parameters to discourage overfitting. They use a cross
validation measure for model selection. One could replace their SVM with a re-
gression probability model and obtain uncertainty estimates as well. However,
they do not directly model discrete heterogeneity and do not consider uncertainty
in their model selection criterion.
There have been other examples of latent class mixture models in the literature.
In another context, (Sobel and Muthen, 2012) used a logistic-normal latent class
mixture model to reflect the assumption that there exists a subpopulation in which
the treatment has zero effect. (Shen and He, 2015) recently applied a similar model
to identify subgroups and developed a corresponding likelihood ratio test for the
existence of latent treatment effect classes. Neither of these approaches allows
for continuous effect modification, however, and both are very sensitive to the as-
sumption of a normal error distribution. We use very flexible error distributions so
that our estimates are robust to departures from normality. Working in a model
evaluation and comparison framework as opposed to Shen’s and He’s hypothesis
testing framework allows us to consider more complex models leading to better
fits and more reliable results.
The structure of this chapter is as follows. In section 2, we describe our approach
in detail, providing specifications of various models that we consider and explain-
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ing the cross validation approach to model selection. In section 3, we provide
simulations illustrating the utility of our approach and the importance of some
of its features. In section 4, we reanalyze a clinical trial for an HIV treatment
that was used as an example in (Shen and He, 2015). We conclude that this trial
exhibits strong discrete heterogeneity, but not as strong as estimated by (Shen and
He, 2015). In section 5, we apply our approach to data from the Oregon Health
Insurance Experiment (OHIE). The OHIE was a natural experiment that arose
when Oregon instituted a lottery to determine who could enroll in a new Medicaid
program with limited openings. This experiment allowed researchers to explore
various public health and economic effects of Medicaid. One prominent finding
was that Medicaid increased emergency department (ED) utilization contrary to
many experts’ predictions. The researchers performed multiple pre-registered and
post hoc comparisons between subgroups and discovered several possible hetero-
geneities. Because the OHIE study contains lots of noncompliers (i.e. lottery
winners who did not enroll in Medicaid and lottery losers who managed to enroll
through other channels), we follow the researchers in performing an instrumen-
tal variable analysis using the principal stratification framework of (Imbens and
Rubin, 1996). Our method extends naturally to this framework because principal
strata are themselves latent classes. When we include all covariates and employ
hierarchical shrinkage priors to deal with multiple comparisons, we do not see
strong evidence of heterogeneity associated with any of the observed covariates.
In section 5, we conclude.
Before proceeding, we prominently note a major limitation. Latent class mix-
ture models are not identifiable for categorical outcome distributions such as the
6
Bernoulli (Titterington, 1985). They are identifiable for the Poisson, negative




We use the potential outcomes framework (Rubin, 1974; Neyman, 1923) which
formalizes the notion that each experimental unit (e.g. patient) has a potential
outcome for each possible treatment assignment that unit might have received. We
get to observe only the potential outcome corresponding to the treatment actually
received. We consider the counterfactual potential outcome that would have been
observed had the treatment assignment been different to be an unobserved random
variable. For the ith unit, let Zi ∈ {0, 1} denote the treatment assignment and Yz,i
the potential outcome corresponding to the possibly counterfactual treatment as-
signment Zi = z. Then Yz=1,i−Yz=0,i is the effect of treatment on unit i. Note that
this individual level causal effect can never be observed because we never observe
both potential outcomes. Still, if we specify a model for the observed data it is
possible to estimate E[Yz=1,i−Yz=0,i|Xi] – the conditional average treatment effect




In Figure 1, we provide a graphical specification that describes all the models we
consider in this paper.
Figure 1.1: Graphical model specification. The dashed lines indicate deterministic
relationships, and the solid lines indicate stochastic relationships.
Intent to Treat Analyses
An interpretation of the nodes of the graph in Figure 1 in the context of a standard
Intent To Treat (ITT) analysis is as follows. The potential outcomes for the ith
unit under treatment assignment Z = z for z in {0, 1} are denoted Yz,i. Again,
for each patient we only observe one of these and the other is treated as missing.
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The expected potential outcome for a unit with covariates Xi and latent class
Gi under treatment assignment Z = z is denoted by µz,i. That is, the µz,i are
the marginal expectations of the potential outcomes conditional on covariates and
latent class. φz are parameters governing the marginal distributions of the poten-
tial outcomes Yz,i apart from their means µz,i. For example, in a normal model,
the φz would be standard deviations. ρ governs the dependence between the two
potential outcomes but is completely unidentified because we never observe both
potential outcomes for any one unit. µz=0 is a function of covariates Xi, latent
class Gi, and parameters βC . µz=1,i = µz=0,i + ∆i, where ∆i denotes the average
treatment effect for units with covariates Xi and latent class Gi. ∆i is a function
of Xi, Gi, and parameters β∆ and λ∆. β∆ determines how treatment effect varies
continuously as a function of covariates, and λ∆ determines the magnitudes of the
discrete differences in treatment effect between latent classes. The probability dis-
tribution that generates Gi is a function of Xi and parameters βG. β∆, λ∆, and βG
are the parameters of interest as together they describe how treatment effect het-
erogeneity is related to covariates. The parameters σG, σ∆, and σC are variances
for shrinkage priors that we place on relevant parameters to avoid overfitting. We
put weakly informative priors on the shrinkage variances themselves so that the
appropriate level of shrinkage is learned from the data.
We make a few remarks on identifiability. We have included the dependence pa-
rameter ρ in the graphical model even though it is completely unidentified by
data. This is because we do not wish to assert that the potential outcomes are
conditionally independent given X and G, as would be implied if ρ were not in
the graph. An important consequence of the unidentifiability of ρ is that it is im-
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possible to obtain an informative posterior or posterior predictive distribution for
an individual level causal effect without making unverifiable assumptions about
the dependence between potential outcomes. We are limited to inferences and
predictions involving only parameters governing the marginal distributions of the
potential outcomes. These parameters are identified by the data, and their pos-
terior distributions are not impacted by ρ (Chib, 2007). Suppose, for example,
we want to predict the causal effect of a drug on a new patient using a hetero-
geneity model of the sort sketched above fit to the clinical trial for the drug. The
most we can extract from from this (or any) model without making assumptions
about ρ is a posterior predictive distribution of the average treatment effect for
patients with the same covariates and (redundantly, unobserved) latent class as
our new patient (i.e. the posterior predictive distribution of that new patient’s
∆ parameter). We can also obtain marginal posterior predictive distributions for
each of that patient’s potential outcomes but not their difference (i.e. the patient’s
treatment effect). Finally, to avoid aliasing issues in parameters of interest, in all
models of this form we require that λGi∆ increases with the latent class label Gi.
The framework of the graphical model in Figure 1 allows for flexibility in the
selection of functional forms, distributions, and number of latent classes. In this
chapter, we only consider linear models for the potential outcomes and logistic re-
gression models for latent class membership. For continuous outcomes, we consider
models with two different error distributions–MNorm with a normal error distri-
bution and MFlex with a more flexible three component Gaussian mixture error
distribution. We demonstrate through simulations in section 3 that violations of
normality in MNorm can lead to biased estimation of parameters of interest, but
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using flexible error distributions as inMflex solves this problem. MNorm andMFlex
are specified below for the case of two latent classes, including application specific
weakly informative priors. Extension to multinomial logistic regression latent class
models is straightforward.
MNorm specification:
Yz=0,i ∼ N(µz=0,i, σz=0)
Yz=1,i ∼ N(µz=1,i, σz=1)
Gi ∼ Bernoulli(pi)












βC ∼ N(0, σC)
βG ∼ N(0, σβG)
β∆ ∼ N(0, σ∆)
σC ∼ Uniform(0, 10)
σG ∼ Uniform(0, 5)
σ∆ ∼ U(0, 10)
σ1 ∼ U(0, 10)
σ0 ∼ U(0, 10)
λ1∆ ∼ N(0, 1000)
λ2∆ − λ1∆ ∼ Truncated_Normal(0, 1000; 0+)
(1.1)
MFlex is the same as MNorm except the MFlex error distributions are each a
11
mean 0 mixture of three Gaussian components. In MFlex,





d1 ∼ N(0, 1000)
d2 ∼ N(0, 1000)
d3 is determined by the constraint that the error distribution has mean 0
q ∼ Dirichlet(1)
(1.2)
Aliasing can arise in the estimation of the parameters governing the flexible error
distribution, but that is not a problem because we are not interested in interpreting
those parameters.
Instrumental Variable Analyses
Sometimes a situation arises in which treatment is not randomly assigned, but an
encouragement to take treatment is randomly assigned. If the random encourage-
ment only affects the outcome through the treatment and is indeed effective at
inducing some people to take the treatment, then the encouragement is referred to
as an ‘instrument’ and an Instrumental Variable (IV) analysis may be performed.
IV analyses estimate the treatment effect in the subpopulation of units that would
take the treatment if and only if encouraged by their value of the instrument. Such
units are referred to as ‘compliers’ and the causal estimand in an IV analysis is
referred to as the Complier Average Causal Effect (CACE). The canonical example
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of an IV setting is a randomized clinical trial with noncompliance. It is frequently
the case in clinical trials that participants do not comply with their treatment
assignments. Patients in the treatment arm may fail to take the treatment, and
those in the control arm may find a way to take the treatment anyway. Thus,
a simple ITT analysis comparing the two arms of the trial estimates the effect
of treatment assignment rather than the effect of the treatment itself. However,
random assignment to the treatment arm can be viewed as an instrument that
encourages patients to take the treatment. An IV analysis with assignment as the
instrument then estimates the effect of treatment on those patients who would
comply with whatever random treatment assignment they happened to receive.
We follow (Sobel and Muthen, 2012) in extending latent class heterogeneity to an
instrumental variable (IV) setting. We consider the case of a randomly assigned bi-
nary instrument Z that encourages a binary treatment D. Suppose without loss of
generality that Z = 1 encourages D = 1. The outcome is denoted by Y . We use a
potential outcomes framework modified for the IV setting. As before, each subject
is assumed to have a potential outcome for each possible treatment assignment
(i.e. YD=1 and YD=0). Each subject is also assumed to have a potential treat-
ment assignment for each possible value of the instrument (i.e. DZ=1 and DZ=0).
Further, each subject has a potential outcome for each possible instrument value
(i.e. YZ=1 and YZ=0). We assume that Z only affects the outcome Y through D, so
YZ=z = YDZ=z . (1.3)
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Under this assumption, the CACE is equivalent to the average causal effect of the
instrument Z on Y among compliers. That is,
CACE = E[YD=1−YD=0|DZ=1 = 1, DZ=0 = 0] = E[YZ=1−YZ=0|DZ=1 = 1, DZ=0 = 0]
(1.4)
In other words, estimating the CACE amounts to estimating the causal effect of
the instrument among a subgroup (compliers). We are therefore interested in mod-
eling the heterogeneity of the effect of the instrument within the (latent) subgroup
of compliers. This places us back in a similar position to the ITT case.
Indeed, models of treatment effect heterogeneity in the instrumental variable set-
ting can be represented by the same graphical model (Figure 1) as the standard
ITT case. However, the interpretation of certain nodes changes, and there are
certain added constraints on parameter values. Latent class (the Gi node in Fig-
ure 1) now encodes compliance status as well as treatment effect class. We follow
(Imbens and Rubin, 1996) in defining four types of subjects or ‘principal strata’:
always takers, never takers, compliers, and defiers. Their definitions are as follows:
always takers would take the treatment regardless of their instrument value; never
takers would not take the treatment regardless of their instrument value; compli-
ers would take the treatment if and only if encouraged by their instrument; and
defiers would take the treatment if and only if discouraged by their instrument.
We make the common assumption that there are no defiers. We get to observe the
principal strata of some subjects, but other subjects’ principal strata are latent.
Units with Z = 1 and D = 0 are definitely never takers, and units with Z = 0
and D = 1 are definitely always takers. But units with Z = 1 and D = 1 could
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either be compliers or always takers, and units with Z = 0 and D = 0 could either
be compliers or never takers. Gi takes one value for never takers, one value for
always takers, and one value for each treatment effect class for compliers to allow
for discrete heterogeneity in the CACE. Because we assume that the instrument
only affects the outcome through the treatment, the instrument effect (represented
by ∆i in Figure 1) must be 0 whenever latent class Gi indicates a never-taker or
always-taker.
In the IV application we consider in this paper, the outcome (number of visits
to the emergency department) is a count variable which we modeled as negative
binomial. We parameterized the outcome in terms of its mean and allowed the log
of the mean to vary discretely with latent class and continuously with covariates.
We call the resulting model MIV , and it is specified below (including application
specific weakly informative priors).
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MIV specification:
Y iz=0 ∼ NegBinom(piz=0, rz=0)
Y iz=1 ∼ NegBinom(piz=1, rz=1)
Gi ∼ Multinomial_Logistic_Regression(Xi; βG)
piz=0 = rGi/(rGi + µ
i
z=0)
















∆ are set to 0




βC ∼ N(0, σC)
βG ∼ N(0, σβG)
β∆ ∼ N(0, σ∆)
σC ∼ Uniform(0, 10)
σG ∼ Uniform(0, 5)
σ∆ ∼ U(0, 10)
r1, . . . , rM ∼ U(0, 10) where M denotes the number of latent classes
λcomplier,1∆ ∼ N(0, 5)
λcomplier,2∆ − λ
complier,1




Identifiability issues can arise for any of the models discussed above when in real-
ity there are no latent classes. In this case, if the error distributions are properly
specified, there can be negligible or no difference in the likelihood between different
parameter settings. For instance, the value of αG (which determines probability of
class membership) is irrelevant if there is no difference between classes. The esti-
mates of βG will still converge to 0 if there are no latent classes, though, so there
is not danger of wrongly concluding that there is discrete heterogeneity associated
with observed covariates.
If the error distributions are misspecified, the latent class component of the model
might help to better model them. If there are no latent classes in reality, an MCMC
may still converge to unique parameter values that best model the misspecified er-
ror distributions. Despite convergence, it is still not correct to interpret latent
class component parameters in terms of heterogeneity in this scenario. But, again,
if there are no latent classes in reality then the estimates of βG should be near
0 and there is not danger of wrongly concluding that heterogeneity is associated
with observed covariates.
Even if there are latent classes in reality, improvements in likelihood from bet-
ter modeling misspecified error distributions can pull estimates away from their
‘correct’ values (that is, the values with correct implications about heterogeneity
if interpreted as intended). That is why it is important to include flexible error
distributions in the model. Simulations in Section 3.2 illustrate this phenomenon.
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Model Evaluation
We follow the framework for model comparison by Bayesian cross validation laid
out in (Vehtari and Lampinen, 2002). A sensible measure of a model M ’s value
is the expected utility of using M to make predictions about future observations
generated by the same process that generated the training data. A Bayesian model
produces a posterior predictive distribution for future outcome ynew given future




where θ denotes the model parameters. The utility of M for predicting a new
outcome is some function u[ynew, xnew, p(y|xnew, D,M)] of the outcome and the
posterior predictive distribution that measures how well the posterior predictive
distribution predicted the outcome. We can estimate the expected utility of a





u[yi, xi, p(yi|xi, D−i,M)] (1.7)
where D−i denotes the data with the ith observation removed and N is the number
of observations in D. This is the LOO-CV estimate of the expected utility of a
model M. To estimate the expected utility on a population whose covariates differ
from the training data in known ways, a weighted average can be used. Because
it is computationally prohibitive to fit the model once for each data point, we ap-
proximate the LOO-CV estimate using an importance sampling scheme proposed
by (Gelfand, 1996; Vehtari and Lampinen, 2002). To compare two models M1 and
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u[yi, xi, p(yi|xi, D−i,M1)− u[yi, xi, p(yi|xi, D−i,M2)]. (1.8)
Generally, the choice of utility function depends on the application. For many
applications, the posterior predictive mean is taken as the forecast and an appro-
priate utility is a monotonic function of the distance of the posterior predictive
mean from the actual outcome. For example, the squared error utility function
would be:
use[ynew, xnew, p(y|xnew, D,M)] = (ynew −
∫
yp(y|xnew, D,M)dy)2. (1.9)
Such utilities are problematic for the purpose of distinguishing models that con-
tain discrete latent class heterogeneity from those that contain only continuous
heterogeneity because they ignore the shape of the posterior predictive distribu-
tion. If there really is heterogeneity, the posterior predictive distribution for a
latent class model will be multimodal and its mean will lie somewhere between the
modes. The posterior predictive distribution for a continuous effect modification
model will usually be unimodal but have a similar mean, so utilities based on the
accuracy of the posterior predictive mean will have low power to distinguish these
potentially quite different models.
A commonly used utility function that does not suffer from this problem is the
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posterior predictive density (ppd):
uppd[ynew, xnew, p(y|xnew, D,M)] = p(ynew|xnew, D,M). (1.10)
This utility rewards models that place lots of posterior predictive probability mass
near future outcome values. A model with a multimodal posterior predictive dis-
tribution would be rewarded for outcomes that lie near any mode and penalized
for outcomes that lie in the low density regions between modes. This utility has
several nice theoretical properties as well. The model with the highest mean pos-
terior predictive density minimizes Kullback Leibler distance to the true model.
Posterior predictive density is also a proper scoring rule (Dawid and Musio, 2014).
A drawback of this utility is that it is sensitive to our choice of error distribution,
and we do not directly care about modeling the error distribution for our applica-
tion. If we use very flexible error distributions for all candidate models, though,
this should not be a serious problem.
In practice, for any given experiment we might consider many candidate mod-
els M1, . . . ,MK with varying numbers of latent classes and functional forms. We
prefer the model with the highest LOO-CV estimated expected posterior predictive
density. However, we want to be mindful of the possibility that, due to sampling
variability, the model with the highest estimated expected utility is not the model
with the highest true expected utility. Each model’s estimated expected utility is
the sample mean of the LOO-CV posterior predictive densities of all the observa-
tions from the experiment. Since the samples of LOO-CV ppds produced by each
model are based on the same observations, they are dependent and their centers
20
can be compared using classical methods for dependent samples such as paired
t-tests or Wilcoxon signed rank tests. Suppose that Mi has the highest estimated
expected utility. We can obtain a conservative p-value for the null hypothesis that
Mi has the highest true expected utility of all models considered by taking the
p-value of the comparison between Mi and the next best model and adjusting for
K multiple comparisons using Holm’s method (Holm, 1979). There are K possible
comparisons we might have made because we would have tested this null hypoth-
esis for whichever model had the best estimated utility. If the p-value we obtain
in this way is very low, we would weight the implications of the top model highly
compared to the other candidates. If the p-value is high, we would not dismiss
the implications of other models with comparable utilities and would accept un-
certainty where those implications conflicted with our chosen model.
Of course, just because a model is the best of those we considered does not mean
it is a good model. We perform posterior predictive checks (Gelman and Xiao,
1995; Bayesian Data Analysis) to try to identify deviations of our chosen model
from the data. If we fail to identify any serious lack of fit, this improves confidence
in the conclusions we draw from our model. If we do identify lack of fit, we can
address them with new models and repeat the process described above.
1.3 Simulations
We apply our approach in several simulated examples demonstrating its capabili-
ties and the importance of some of its features. First, we demonstrate the ability
of cross validation to distinguish between discrete and continuous heterogeneity.
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Next, we illustrate the necessity of flexible error distributions. All code for simu-
lations discussed in this section is available at zshahn.columbia.edu.
In Sim1, we generated data from MNorm with the following settings:
Yz=0,i ∼ N(µz=0,i, 1)
Yz=1,i ∼ N(µz=1,i, 1)
Gi ∼ Bernoulli(pi)
logit(pi) = −1 +Xi · (−2,−1, 0, 1, 2)
µiz=0 = 51{Gi = 2}+Xi · (−2,−1, 0, 1, 2)




We simulated a two armed clinical trial with 500 patients in each arm. X con-
sisted of 5 predictor variables generated from a standard normal distribution. Both
continuous and discrete heterogeneity was present. We then fit three models to
this data: MFlex, MContinuousF lex (which is identical to MFlex but without a discrete
heterogeneity component), and MConstantF lex (which is identical to MFlex but without
discrete or continuous heterogeneity). Below, we see that the posterior of MFlex
is accurate and clearly does not sacrifice too much precision for the robustness
gained from flexible error distributions.
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Figure 1.2: The results of fitting MFlex to Sim1. The dots are the true parameter
values and the lines are 95% credible intervals.
The LOO-CV estimated expected posterior predictive densities forMFlex,MContinuousF lex ,
and MConstantF lex were 0.22, 0.12, and 0.12 respectively. A paired t-test comparing
MFlex andMContinuousF lex rejected the null hypothesis that E[uMFlex−uMContinuousFlex ] ≤ 0
with p-value numerically 0. Hence, cross validation decisively favored the correct
heterogeneity model MFlex.
In Sim2, we generated data from a model we will callMContinuousNorm , which is identical
to MNorm but without a discrete component:
Yz=0,i ∼ N(µz=0,i, 1)
Yz=1,i ∼ N(µz=1,i, 1)
µiz=0 = Xi · (−2,−1, 0, 1, 2)





Again, we simulated a clinical trial with 500 patients in each arm. X again con-
sisted of 5 predictor variables generated from a standard normal distribution. We
then fit the same three models to this data that we fit to Sim1. MFlex exhibited
the identifiability issues discussed in the previous section that can arise when there
are no latent classes in the true data generating process and the error distribu-
tions are correctly (over-)specified. Different MCMC chains got stuck at very high
or low values of αG, but all chains converged to 0 for βG and the correct values
for β∆. The LOO-CV estimated expected posterior predictive densities for MFlex,
MContinuousF lex , and MConstantF lex were .2799, .2801, and 0.133 respectively. The p-value
from a paired t test comparing the samples from MFlex and MContinuousF lex was 0.001.
So cross validation selected the simplest correct model MConstantF lex .
1.3.1 The Importance of Flexible Error Distributions
We simulated data from a model similar to MNorm but with highly skewed error
distributions:
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Y iz=0 ∼ Gamma(µiz=0, shape0, scale0)
Y iz=1 ∼ Gamma(µiz=1, shape1, scale1)
Gi ∼ Bernoulli(pi)
logit(pi) = −1 +Xi · (−2,−1, 0, 1, 2)
µiz=0 = 51{Gi = 2}+Xi · (−2,−1, 0, 1, 2)





X consisted of 5 predictor variables generated from a standard normal distribution.
Gamma(µ, shape, rate) denotes a Gamma distribution shifted to have mean µ. We
chose shape0 = shape1 = 1 and scale0 = scale1 = 10 so that the error distributions
were highly skewed as in the figure below.
Figure 1.3: Skewed Error Distribution
We fit the models MNorm and MFlex described in the previous section to the data
simulated from the above process. The two models only differed in their error
distributions and were correctly specified in all other respects. Figure 4 compares
the models’ estimates of certain parameters of interest. We see that the MNorm
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Figure 1.4: Comparison of MNorm and MFlex
estimates are off target for some parameters, including the λ2∆ − λ1∆ parameter
that represents the magnitude of discrete heterogeneity between latent classes.
The MFlex estimates are fairly accurate for all parameters. These results illustrate
sensitivity to misspecification of the error distribution and reassure us that the
strategy of employing a flexible (mixture of normals) error distribution is sufficient
to handle the problem.
To illustrate model comparison in this setting, we also consider MContinuousF lex .
We use LOO-CV to compare MContinuousF lex to MFlex, which we know to be the supe-
rior model. In our simulated example, the LOO-CV estimated expected posterior
predictive density of MFlex was .04 compared to .03 for MContinuousF lex . A paired
t-test comparing the samples of LOO-CV ppd’s from the two models rejected the
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null hypothesis that E[uMFlex − uMContinuousFlex ] ≤ 0 with p-value numerically 0.
1.4 Re-analysis of Data from the ACTG 320 Clin-
ical Trial
The ACTG 320 trial compared two AIDS treatments–a combination of indinavir,
zidovudine, and lamivudine versus just zidovudine and lamivudine. Following
(Shen and He, 2015) who themselves follow (Hammer et al., 1997) and (Zhao et
al., 2013), we take change in CD4 count at the 24th week of treatment as the
response variable, exclude patients with missing outcome values or extreme CD4
counts, and ignore any bias that we may induce by these exclusions. We are left
with a dataset of 800 patients. A summary of the data is included in the Appendix.
Before fitting any models, we test the null hypothesis of a constant treatment
effect using Rosenbaum’s covariance adjustment test (Rosenbaum, 2002). The
test produces a p value that is approximately 0, so we are quite certain that there
is heterogeneity. The question remains whether it is related to observed covariates
and whether we can effectively model it.
We fit multiple models and compare them using LOO-CV with posterior predic-
tive density as the utility function. In some models, we use just the 3 covariates
that Shen and He considered (baseline CD4, baseline RNA, and age), while in
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others we take advantage of regularization to include the 9 other variables that
were available. M1 is Shen and He’s model with two latent classes, a common
normal error distribution for all patients, no continuous effect modification, and
just 3 covariates. M2 is a constant effect model with separate flexible error distri-
butions for each treatment group. Note that ’constant effect’ is a misnomer, since
the distinct error distributions for the two treatment arms allow for heterogeneity,
just not associated with the covariates. M3 is the same as M1 but with separate
flexible error distributions for each treatment group. M4 is the same as M3 but
includes all 12 covariates. M5 is a continuous effect modification model with sep-
arate flexible error distributions for each treatment group and only 3 covariates.
M6 is the same as M5 but includes all 12 covariates. M7 is a 2 latent class mixture
model with continuous effect modification and flexible error distributions and only
3 covariates. M8 is the same as M7 but includes all 12 available covariates. M9
is the same as M8 except that it has 3 latent classes instead of 2. All continuous
effect modification was specified as linear, and all latent class membership models
were specified as logistic or, in the case of M9, multinomial logistic. The table
at the top of Figure 5 summarizes key attributes of the models. A summary of
parameter estimates from select models is in the Appendix.
Figure 5 depicts the LOO-CV estimated expected posterior predictive densities
of each model. The first thing that jumps out in this plot is that M1, which is
Shen and He’s model with a normal error distribution, performs far worse than
the other models which all use flexible error distributions. This is not necessarily
meaningful, however. Our parameters of interest do not govern the error distri-
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Figure 1.5: LOO-CV estimated expected posterior predictive densities of each
model
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bution, so the utility could be rewarding these models purely for better modeling
an aspect of the data that is not important to us. But comparing the parameter
estimates of M3 (which is Shen and He’s model with flexible error distributions)
to M1, we see that there are substantive differences. The estimated difference in
treatment effects between latent classes is significantly smaller in M3 than in M1.
Observing that the residuals are highly skewed and recalling the lessons learned
from the simulation in Section 3.1, we suspect that the misspecified error distribu-
tion of M1 biased the estimates of parameters of interest. However, it is still true
that much of the difference in expected utility could be due to error distribution
alone.
Next we turn our attention to the models with flexible error distributions. The
most complex model, M9, has the highest expected utility. When comparing mod-
els, we note that the estimated utilities are the sample means of the LOO-CV
posterior predictive densities of the 800 observations. Since the samples of LOO-
CV ppds produced by each model are based on the same observations, they are
dependent and can be compared using classical methods for dependent samples
such as paired t-tests or Wilcoxon signed rank tests. Paired t-tests indicate that
the sample mean LOO-CV utility for M9 is statistically significantly greater than
the sample mean LOO-CV utilities of every other model. We can obtain a con-
servative p-value for the null hypothesis that M9 has the highest true expected
utility of all models considered by taking the p-value of the comparison between
M9 and the next best model (M8) and adjusting for multiple comparisons using
Holm’s method. The paired t-test comparing M9 to M8 had p-value .006, and
adjusting for the other 7 similar comparisons we might have made (i.e. testing
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whether models 2 through 8 were the best) yields p ≈ .04. That is, the probability
of M9 having such a superior estimated utility due to sampling variation alone if
any of the other models had true expected utilities as good as M9’s is less than
.04 (‘less than’ because our p-value is conservative). This indicates strong but
not necessarily overwhelming support for M9, so we would not completely dismiss
other models with similar utilities such as M8, M7, and M4. We definitely prefer
M9 but would take its implications with a grain of salt if they contradicted one of
the other models with fairly similar utility.
We now take a closer look at what the models said about heterogeneity. Where
comparisons between models could be made, the models were generally in agree-
ment. First, every model found that heterogeneity was associated with the co-
variates (apart from the constant model M2, obviously). Of the three covariates
that were included in every model (except M2), baseline CD4 count and RNA
levels, which we will denote cd40 and rna0, were unanimously positively associ-
ated with treatment effect after adjusting for other covariates. The models that
contained all 12 covariates also agreed that weight was positively associated and
prior zidovudine exposure negatively associated with treatment effect adjusting for
other covariates. (We will omit ‘adjusting for other covariates’ for the remainder
of this discussion, but it should be understood that all associations might depend
on which other covariates were included in the model.)
Every model that contained both continuous and discrete heterogeneity compo-
nents (M9, M8, andM7) attributed most covariate associated heterogeneity to dis-
crete differences between latent classes. Every model that included latent classes
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agreed that there was a substantial difference of about 60-80 CD4 count between
the highest treatment effect class and the lowest. The three class model, M9, also
included a middle class with estimated treatment effect approximately 10 higher
than in the lowest class. The treatment effect in the low class for an average patient
was about 45-55 CD4 count in all models. All latent class models agreed that cd40
and rna0 were positively associated with membership in the highest class. The
models with 12 covariates also agreed that weight was positively associated and
prior zidovudine negatively associated with membership in the highest class. In
the two class models (M3,M4,M7, andM8), strength of association with class mem-
bership is easily discerned from the posterior distributions of the relevant logistic
regression coefficients from the βG parameter. In the preferred three class model,
in which class is determined by a multinomial logistic regression, the relationship
between βG and the nature of the association is more subtle. Figure 6 compares the
M9 posterior distributions of probability of membership in the highest effect class
for three hypothetical patients–one with the maximum observed value of cd40, one
with the median observed value of cd40, and one with the minimum observed value
of cd40. All three hypothetical patients were assigned median values for all other
covariates. Comparing the high and medium patients, we see that the high cd40
value makes low probabilities of membership in the highest treatment effect class
less likely but does not alter the mode. For very low values of cd40, membership in
the high treatment effect class is virtually impossible. So M9 appears to pick up
on a nonlinear aspect to the association between cd40 and highest treatment effect
class membership probability. Low values of cd40 are also strongly associated with
membership in the middle class.
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Figure 1.6: Posterior predictive distributions from model M9 of probability of
membership in the highest treatment effect class for hypothetical patients with
low, median, and high cd40 values
Figure 1.7: Posterior predictive distributions from model M9 of the ∆ parameter
for hypothetical patients with low, median, and high rna0 values.
The models that contained both continuous and discrete heterogeneity compo-
33
nents (M9, M8, and M7) also all detected a possible moderate linear association
with rna0 and no other significant linear associations. So our preferred model
M9 and all the other credible models together imply mostly discrete heterogeneity
associated with cd40, rna0, weight, and zidovudine exposure along with possible
modest continuous effect modification by rna0. The strong performance of M9
might be attributed to the more flexible relationships it allows between covariates
and high effect class membership. A more thorough analysis would explore models
with nonlinear regressions, more than 3 latent classes, interactions among covari-
ates, and distinct error distributions for each latent class instead of just for each
treatment group.
As a last step, we performed some basic posterior predictive checks (Gelman et al.,
1996) to affirm thatM9 not only outperforms the other candidates but also fits the
data reasonably well. First, Figure 8 compares a histogram of the outcomes from
the real trial to a histogram of fake outcomes that were simulated from the pos-
terior mean values of the parameters from M9 and the observed covariate values.
The distributions are remarkably similar. We then simulated 1000 fake data sets
from the posterior predictive distribution of M9, computed summary statistics of
each fake data set, and checked whether the corresponding summary statistics of
the true data fall within the range of the simulations. The exercise is summarized
in figure 9 below, in which the red dots indicate the summary statistic values in
the real data. The model appears to fit well by these criteria.
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Figure 1.8: The distribution of the outcome variable in the trial (right) and a draw
from the M9 posterior predictive distribution of the outcome variable (left)
Figure 1.9: Posterior Predictive Checks of M9
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1.5 The Oregon Health Insurance Experiment (OHIE)
Study
1.5.1 Description of the study and the data
In 2008, Oregon instituted a lottery to determine who could enroll in a new Med-
icaid program with limited openings. The randomness of the lottery induced a
natural experiment that has allowed researchers to explore various public health
and economic effects of Medicaid (Taubman et al., 2014). One important health
economic question was what effect if any Medicaid might have on emergency de-
partment (ED) utilization. The intuitive and naive guess would be that health
insurance would increase utilization by decreasing cost. However, many experts
had predicted that expanding health insurance would actually decrease ED uti-
lization for two main reasons. First, uninsured patients sometimes go to EDs
for problems that could be addressed in a primary care setting because, unlike
primary care physicians, EDs cannot turn patients away for being unable to af-
ford treatment. Second, assuming Medicaid coverage would increase primary care
utilization, regular monitoring of chronic conditions at primary care visits might
prevent flareups that necessitate trips to the ED.
Taubman et al. addressed this question by looking at ED utilization among the
24,000 lottery participants who lived in Portland. They matched these lottery
participants to medical records from 12 hospitals that accounted for almost all ED
visits for Portland residents over the period of the study. Unfortunately, because
many lottery winners did not go on to actually enroll in Medicaid and some lot-
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tery losers managed to enroll through other channels, Taubman et al. could not
simply compare lottery winners to losers to directly estimate the average causal
effect (ACE) of Medicaid coverage. In these situations, the best one can do is
to estimate the ‘Complier Average Causal Effect’ (CACE) using an instrumental
variable analysis. The CACE is the average causal effect of Medicaid coverage on
those lottery participants who would enroll in Medicaid if and only if they won the
lottery (Imbens and Rubin, 1996; Rubin and Frangakis, 2002), i.e. the compliers.
Taubman et al estimated the CACE to be positive with high confidence, support-
ing the naive and intuitive prediction that Medicaid coverage would increase ED
utilization.
Restricting their data to approximately 10,000 lottery participants who filled out
a survey containing questions pertaining to pre-treatment covariates, Taubman et
al. explored heterogeneity in the CACE by performing both pre-registered and
post hoc subgroup comparisons. They discovered several possible disparities in
treatment effect (e.g. between smokers and non-smokers and between people with
and without a prior serious chronic disease) but did not adjust either the pre-
registered or the post-hoc comparisons for multiple testing. See the Appendix for
tables summarizing the data and covariates.
1.5.2 Results of application to OHIE
We applied model MIV defined in Section 2 to the OHIE data. In the context
of the OHIE, the definitions of the principal strata are as follows: always takers
would enroll in Medicaid regardless of whether they won the lottery; never takers
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would not enroll in Medicaid regardless of whether they won the lottery; compliers
would enroll if they won the lottery and not enroll if they lost; and defiers would
enroll if they lost and not enroll if they won. We make the common assumption
that there are no defiers. We get to observe the principal strata of some subjects,
but other subjects’ principal strata are latent. Lottery winners who don’t enroll
in Medicaid are definitely never takers, and lottery losers who do enroll are defi-
nitely always takers. But winners who enroll could either be compliers or always
takers, and losers who do not enroll could either be compliers or never takers.
Gi takes one value for never takers, one value for always takers, and one value
for each treatment effect class for compliers to allow for discrete heterogeneity in
the CACE. The model specified two treatment effect classes within the subgroup
of compliers. Because we assume that the instrument only affects the outcome
through the treatment, the instrument effect (represented by ∆i in Figure 1) must
be 0 whenever latent class Gi indicates a never-taker or always-taker.
When we included all recorded baseline covariates and used hierarchical shrink-
age priors, we did not find evidence that treatment effect among compliers was
associated with any of the recorded covariates. (Or, assuming that all covariates
are associated with treatment effect at least a little bit, we did not find strong
evidence of the direction of any of the associations.) The posterior distributions of
all components of βG and β∆ were centered near zero with substantial probability
mass on either side. A summary of the results is in the Appendix.
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1.6 Conclusion
We have illustrated a general Bayesian framework for modeling treatment effect
heterogeneity in experiments with non-categorical outcomes. Our modeling ap-
proach incorporates latent class mixture components to capture discrete hetero-
geneity and regression interaction terms to capture continuous heterogeneity. Flex-
ible error distributions allow robust posterior inference on parameters of interest.
Hierarchical shrinkage priors on relevant parameters address multiple comparisons
concerns. Leave-one-out cross validation estimates of expected posterior predictive
density obtained through importance sampling, together with posterior predictive
checks, provide a convenient method for model selection and evaluation.
Simulated and real examples demonstrate the utility of this framework and the
importance of its various features. The method provides convincing evidence that
the heterogeneity in the the ACTG HIV trial is truly discrete and characterizes
potential subgroups in terms of baseline covariates. Parameter estimates differ
substantially from a prior analysis using a similar method (though the subjective
interpretation of the output remains the same) as a result of using flexible error
distributions, the importance of which is illustrated in simulations. In the IV anal-
ysis of the OHIE data, shrinkage priors serve their purpose and prevent premature
identification of heterogeneities that may be due to multiple comparisons.
We see four immediate opportunities for future work. First, it should be relatively
straightforward to develop implementations of this approach for other specialized
outcome models, in particular for survival analyses. Second, if one could obtain
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stable estimates of Bayes factors, possibly using the method of (Chib and Jeliazkov,
2001), more formal methods for model comparison with certain desirable proper-
ties would be available, and model averaged estimates of some relevant quantities
could be computed. Third, variational Bayes approximations to the posteriors of
these models would enable applications to experiments with very large numbers of
covariates. And finally, nonparametric implementations could mitigate concerns
about model misspecification.
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1.8 Appendix A: ACTG Trial
1.8.1 Data Summary
Table 1.1: ACTG Data Summary
Min. 1st.Qu. Median Mean 3rd.Qu.
Female 0.00 0.00 0.00 0.16 0.00
Hemophilia 0.00 0.00 0.00 0.03 0.00
Weight -4.21 -0.64 -0.07 -0.00 0.57
Karnofsky -2.72 -0.15 -0.15 0.00 1.14
Prior_ZDV -0.86 -0.69 -0.31 0.00 0.35
Age -2.60 -0.68 -0.12 -0.00 0.58
CD4_0 -3.96 -0.65 0.26 -0.00 0.83
RNA_0 -4.85 -0.47 0.15 -0.00 0.68
IV_now 0.00 0.00 0.00 0.00 0.00
IV_past 0.00 0.00 0.00 0.14 0.00
Black or Hisp 0.00 0.00 0.00 0.44 1.00
Other_race 0.00 0.00 0.00 0.01 0.00
The Karnofsky score indicates the severity of the disease. Prior_ZDV indicates
whether the patient had used similar drugs to those in the trial in the past. CD4_0
is baseline CD4 count, RNA_0 is baseline levels of HIV RNA in the blood. IV_now
and IV_past indicate whether the patient is a current or past IV drug user, re-
spectively. Below is a histogram of the outcome variable over all patients in the
trial:
Figure 1.10: Histogram of Week 24 CD4 Count
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1.8.2 Parameter Estimates For Select Models of ACTG Trial
Data
M9 Posterior Summary for Relevant Parameters:
Median Mean SD .05 .95
α2G -2.56 -2.90 4.01 -10.10 3.14
α3G -0.13 -0.13 0.29 -0.58 0.37
β2G,1 -1.53 -2.10 4.26 -9.68 4.11
β2G,2 -2.74 -2.99 6.67 -13.99 8.13
β2G,3 -7.29 -7.35 5.12 -15.87 1.38
β2G,4 -2.43 -2.73 2.21 -6.74 0.19
β2G,5 -1.24 -1.44 2.59 -5.71 2.23
β2G,6 -0.22 0.04 2.52 -3.49 4.81
β2G,7 -10.85 -10.94 5.26 -19.97 -2.97
β2G,8 -4.44 -4.58 2.67 -9.28 -0.84
β2G,9 0.85 1.31 6.38 -8.78 12.62
β2G,10 2.91 3.55 4.66 -3.16 12.10
β2G,11 -3.01 -3.48 3.70 -10.00 1.91
β2G,12 1.10 1.54 6.48 -9.14 12.84
β3G,1 0.03 0.05 0.25 -0.33 0.52
β3G,2 -0.03 -0.05 0.32 -0.61 0.43
β3G,3 -0.13 -0.14 0.19 -0.46 0.14
β3G,4 0.00 -0.00 0.15 -0.25 0.23
β3G,5 -0.21 -0.22 0.17 -0.52 0.02
β3G,6 -0.04 -0.04 0.16 -0.31 0.21
β3G,7 -0.15 -0.18 0.26 -0.65 0.17
β3G,8 0.33 0.34 0.21 0.00 0.70
β3G,9 -0.01 -0.02 0.32 -0.55 0.48
β3G,10 -0.06 -0.08 0.26 -0.54 0.29
β3G,11 0.16 0.19 0.24 -0.16 0.61
β3G,12 0.00 0.01 0.31 -0.48 0.52
β∆,1 0.27 0.61 3.99 -5.68 7.60
β∆,2 -1.22 -2.28 4.92 -11.47 3.98
β∆,3 1.50 1.97 2.92 -2.12 7.27
β∆,4 0.10 0.29 2.69 -3.92 4.96
β∆,5 0.44 0.62 2.71 -3.76 5.33
β∆,6 0.94 1.25 2.62 -2.90 5.93
β∆,7 1.33 1.95 3.22 -2.41 7.94
β∆,8 4.63 4.95 3.68 -0.10 11.46
β∆,9 0.10 0.24 4.72 -7.22 8.11
β∆,10 -0.65 -1.14 3.97 -8.05 4.74
β∆,11 -1.05 -1.62 3.70 -8.38 3.87
β∆,12 -0.01 0.06 4.57 -7.40 7.48
λ1∆ 45.64 45.60 6.34 35.35 55.81
λ2∆ − λ1∆ 8.98 10.61 7.88 1.04 26.03
λ3∆ − λ2∆ 62.78 62.26 11.81 41.67 80.67
σC 4.78 4.78 1.61 1.18 7.25
σ∆ 3.80 4.02 2.26 0.61 8.13
σ1G 6.24 6.03 2.42 1.85 9.59
σ2G 0.27 0.29 0.15 0.08 0.57
The multinomial logistic regression parameters αjG and β
j

































The parameter indices match the rows of the table in Appendix A.
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M8 Posterior Summary for Relevant Parameters:
Median Mean SD .05 .95
αG -1.30 -1.34 0.42 -2.10 -0.73
βG,1 0.21 0.23 0.33 -0.28 0.82
βG,2 -0.07 -0.08 0.47 -0.87 0.66
βG,3 0.22 0.22 0.16 -0.04 0.48
βG,4 0.01 0.00 0.17 -0.28 0.28
βG,5 -0.28 -0.30 0.19 -0.63 -0.00
βG,6 0.07 0.08 0.17 -0.20 0.36
βG,7 0.64 0.67 0.28 0.26 1.17
βG,8 0.59 0.59 0.21 0.25 0.94
βG,9 -0.07 -0.08 0.51 -0.93 0.71
βG,10 -0.16 -0.18 0.32 -0.74 0.31
βG,11 0.31 0.33 0.29 -0.12 0.83
βG,12 0.02 0.02 0.51 -0.80 0.86
β∆,1 -0.11 -0.16 3.93 -6.66 6.39
β∆,2 -1.10 -1.97 4.67 -10.70 4.36
β∆,3 1.37 1.67 2.70 -2.30 6.47
β∆,4 0.25 0.43 2.65 -3.86 5.03
β∆,5 0.51 0.69 2.72 -3.75 5.35
β∆,6 1.02 1.28 2.61 -2.73 5.86
β∆,7 -0.03 -0.02 2.58 -4.24 4.34
β∆,8 4.90 5.19 3.69 -0.02 11.70
β∆,9 0.10 0.28 4.58 -7.07 8.06
β∆,10 -0.81 -1.41 4.01 -8.74 4.37
β∆,11 -1.18 -1.73 3.81 -8.68 3.76
β∆,12 0.08 0.24 4.43 -6.84 7.64
λ1∆ 51.49 51.57 5.80 42.23 61.18
λ2∆ − λ1∆ 57.62 57.34 11.81 37.32 76.07
σC 2.08 2.26 1.01 1.02 4.18
σ∆ 3.78 3.97 2.17 0.63 8.04
σG 0.45 0.48 0.20 0.23 0.84
Parameters correspond exactly to MFlex.
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M1 Posterior Summary for Relevant Parameters:
Median Mean SD .05 .95
αG -1.32 -1.33 0.25 -1.75 -0.95
βG,1 0.48 0.49 0.22 0.15 0.86
βG,2 0.79 0.80 0.24 0.42 1.21
βG,3 -0.14 -0.14 0.21 -0.50 0.18
λ1∆ 36.26 36.25 4.66 28.70 43.74
λ2∆ − λ1∆ 105.35 105.50 12.99 84.41 127.01
This is Shen and He’s model. It is a special case of MNorm without continuous
heterogeneity or regularization.
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1.9 Appendix B: OHIE
1.9.1 Data Summary
Table 1.2: OHIE Covariate Summary
Min. .25 Median Mean .75 Max.
English 0.00 0.00 0.00 0.10 0.00 1.00
Female 0.00 0.00 1.00 0.56 1.00 1.00
First_Day 0.00 0.00 0.00 0.09 0.00 1.00
Age -1.68 -0.91 -0.05 0.00 0.81 1.92
SNAP 0.00 0.00 1.00 0.55 1.00 1.00
TANF 0.00 0.00 0.00 0.02 0.00 1.00
Prior_ED 0.00 0.00 0.00 0.33 1.00 1.00
Edu 0.00 1.00 1.00 0.80 1.00 1.00
Black 0.00 0.00 0.00 0.12 0.00 1.00
Hisp 0.00 0.00 0.00 0.18 0.00 1.00
Other_Race 0.00 0.00 0.00 0.15 0.00 1.00
Smoker 0.00 0.00 0.00 0.43 1.00 1.00
Prior_DX 0.00 0.00 1.00 0.56 1.00 1.00
English indicates whether the patient required instructions in a language other
than English. First_Day indicates whether the patient signed up for the Medicaid
lottery on the first possible day. Age was of course standardized. SNAP and TANF
indicate whether the patient had ever enrolled in other state assistance programs.
Prior_ED indicates whether the patient had visited the ED in the year prior to
the lottery. Prior_DX indicates whether the patient had a serious chronic disease
such as diabetes, asthma, or cancer. Below is a histogram of ED utilization of all
lottery participants:
Figure 1.11: Histogram of ED Utilization
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1.9.2 Posterior Summary of MIV Applied to OHIE
Median Mean SD .025 .975
α1G 0.00 0.00 0.00 0.00 0.00
α2G 0.00 0.13 9.70 -18.25 19.63
α3G -0.17 -0.21 9.30 -17.93 16.94
α4G 1.12 0.97 9.93 -18.89 19.51
β1G,1 0.00 0.00 0.00 0.00 0.00
β2G,1 -0.00 -0.06 2.39 -5.42 5.34
β3G,1 -0.01 -0.13 2.35 -5.48 4.97
β4G,1 -0.01 -0.12 2.38 -5.46 4.86
β1G,2 0.00 0.00 0.00 0.00 0.00
β2G,2 -0.00 -0.03 2.44 -5.47 5.34
β3G,2 0.00 -0.02 2.36 -5.57 5.08
β4G,2 -0.00 -0.02 2.39 -5.27 5.34
β1G,3 0.00 0.00 0.00 0.00 0.00
β2G,3 0.00 0.13 2.31 -4.78 5.62
β3G,3 0.00 0.03 2.33 -5.12 5.44
β4G,3 -0.00 0.04 2.36 -4.98 5.26
β1G,4 0.00 0.00 0.00 0.00 0.00
β2G,4 0.00 0.08 2.53 -5.64 5.97
β3G,4 0.00 0.01 2.36 -5.41 5.49
β4G,4 0.00 0.04 2.33 -4.90 5.40
β1G,5 0.00 0.00 0.00 0.00 0.00
β2G,5 0.00 -0.03 2.48 -5.48 4.92
β3G,5 -0.00 0.01 2.47 -5.24 5.57
β4G,5 0.00 -0.00 2.51 -5.25 5.54
β1G,6 0.00 0.00 0.00 0.00 0.00
β2G,6 0.00 0.12 2.37 -4.99 5.66
β3G,6 -0.00 0.01 2.28 -4.94 4.99
β4G,6 0.01 0.08 2.46 -5.13 5.69
β1G,7 0.00 0.00 0.00 0.00 0.00
β2G,7 -0.00 -0.08 2.30 -5.44 4.80
β3G,7 -0.01 -0.12 2.35 -5.36 5.10
β4G,7 -0.00 -0.02 2.24 -5.21 4.81
β1G,8 0.00 0.00 0.00 0.00 0.00
β2G,8 -0.01 -0.11 2.44 -5.71 5.00
β3G,8 0.00 0.07 2.32 -4.97 5.24
β4G,8 0.00 -0.02 2.40 -5.37 5.21
β1G,9 0.00 0.00 0.00 0.00 0.00
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β2G,9 0.01 0.14 2.48 -4.94 5.79
β3G,9 -0.00 0.06 2.35 -4.99 5.51
β4G,9 -0.00 -0.03 2.40 -5.27 5.30
β1G,10 0.00 0.00 0.00 0.00 0.00
β2G,10 0.00 -0.06 2.36 -5.42 5.14
β3G,10 0.00 0.03 2.45 -5.06 5.94
β4G,10 -0.01 -0.05 2.31 -5.18 4.84
β1G,11 0.00 0.00 0.00 0.00 0.00
β2G,11 -0.00 -0.06 2.33 -5.30 5.02
β3G,11 0.01 0.11 2.42 -5.09 5.48
β4G,11 0.01 0.04 2.25 -4.87 4.94
β1G,12 0.00 0.00 0.00 0.00 0.00
β2G,12 0.01 0.10 2.45 -5.48 5.61
β3G,12 0.00 0.07 2.31 -5.07 5.10
β4G,12 0.01 0.12 2.35 -4.87 5.65
β1G,13 0.00 0.00 0.00 0.00 0.00
β2G,13 -0.02 -0.19 2.47 -5.71 5.15
β3G,13 0.01 0.15 2.36 -4.78 5.66
β4G,13 -0.00 -0.01 2.41 -5.14 5.22
β1∆,1 0.00 0.00 0.00 0.00 0.00
β2∆,1 0.00 0.00 0.00 0.00 0.00
β3∆,1 -0.00 -0.00 0.11 -0.24 0.24
β4∆,1 -0.00 -0.01 0.10 -0.24 0.18
β1∆,2 0.00 0.00 0.00 0.00 0.00
β2∆,2 0.00 0.00 0.00 0.00 0.00
β3∆,2 -0.01 -0.03 0.09 -0.25 0.13
β4∆,2 -0.03 -0.06 0.10 -0.34 0.09
β1∆,3 0.00 0.00 0.00 0.00 0.00
β2∆,3 0.00 0.00 0.00 0.00 0.00
β3∆,3 -0.02 -0.05 0.11 -0.34 0.12
β4∆,3 0.01 0.03 0.10 -0.15 0.29
β1∆,4 0.00 0.00 0.00 0.00 0.00
β2∆,4 0.00 0.00 0.00 0.00 0.00
β3∆,4 0.00 0.00 0.07 -0.14 0.17
β4∆,4 -0.02 -0.04 0.08 -0.22 0.08
β1∆,5 0.00 0.00 0.00 0.00 0.00
β2∆,5 0.00 0.00 0.00 0.00 0.00
β3∆,5 0.01 0.04 0.10 -0.13 0.30
β4∆,5 0.01 0.02 0.09 -0.16 0.23
β1∆,6 0.00 0.00 0.00 0.00 0.00
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β2∆,6 0.00 0.00 0.00 0.00 0.00
β3∆,6 0.01 0.02 0.11 -0.20 0.27
β4∆,6 -0.00 -0.00 0.11 -0.25 0.23
β1∆,7 0.00 0.00 0.00 0.00 0.00
β2∆,7 0.00 0.00 0.00 0.00 0.00
β3∆,7 0.00 0.01 0.10 -0.20 0.24
β4∆,7 -0.00 -0.01 0.09 -0.22 0.18
β1∆,8 0.00 0.00 0.00 0.00 0.00
β2∆,8 0.00 0.00 0.00 0.00 0.00
β3∆,8 -0.00 -0.00 0.09 -0.20 0.19
β4∆,8 -0.02 -0.05 0.11 -0.35 0.11
β1∆,9 0.00 0.00 0.00 0.00 0.00
β2∆,9 0.00 0.00 0.00 0.00 0.00
β3∆,9 -0.00 -0.01 0.09 -0.24 0.16
β4∆,9 0.00 0.01 0.10 -0.18 0.23
β1∆,10 0.00 0.00 0.00 0.00 0.00
β2∆,10 0.00 0.00 0.00 0.00 0.00
β3∆,10 -0.01 -0.03 0.11 -0.30 0.16
β4∆,10 0.02 0.04 0.10 -0.12 0.31
β1∆,11 0.00 0.00 0.00 0.00 0.00
β2∆,11 0.00 0.00 0.00 0.00 0.00
β3∆,11 -0.00 -0.02 0.10 -0.25 0.16
β4∆,11 -0.01 -0.02 0.10 -0.26 0.17
β1∆,12 0.00 0.00 0.00 0.00 0.00
β2∆,12 0.00 0.00 0.00 0.00 0.00
β3∆,12 0.02 0.05 0.11 -0.12 0.30
β4∆,12 0.01 0.03 0.10 -0.16 0.26
β1∆,13 0.00 0.00 0.00 0.00 0.00
β2∆,13 0.00 0.00 0.00 0.00 0.00
β3∆,13 -0.00 -0.01 0.09 -0.22 0.16
β4∆,13 0.01 0.03 0.10 -0.13 0.29
λ1∆ 0.00 0.00 0.00 0.00 0.00
λ2∆ 0.00 0.00 0.00 0.00 0.00
λ3∆ 0.11 0.09 0.19 -0.37 0.41
λ4∆ 0.47 0.48 0.17 0.19 0.86
r1 0.48 0.48 0.03 0.43 0.54
r2 0.84 0.84 0.08 0.70 1.00
r3 5.79 6.00 1.94 2.85 9.72
r4 0.43 0.44 0.06 0.33 0.57
σC 0.52 0.53 0.06 0.42 0.65
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σG 1.92 1.97 1.39 0.01 4.73
σ∆ 0.07 0.09 0.07 0.01 0.24
G = 1 corresponds to never takers, G = 2 corresponds to always takers, G = 3
corresponds to low treatment effect class compliers, and G = 4 corresponds to high
treatment effect class compliers. The multinomial logistic regression parameters
αjG and β
j
























∆ = 0 because there is no treatment effect, and hence no treatment
effect heterogeneity, for never takers and always takers. The λ∆ and r parameters
vary by group but could just be modeling the error distribution and are therefore
not interpretable in terms of heterogeneity. The regression coefficient parameter
indices match the rows of the covariate summary table.
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Chapter 2
Ensembles of Granger Graphs
(EGG) for Causal Discovery in High
Dimensional Longitudinal Databases
2.1 Introduction
Health care decisions frequently depend on observational studies of health insur-
ance claims databases. Setting aside important issues relating to data quality (e.g.
Lewis et al., 2008; Harrold et al., 2007), such databases can be said to longitu-
dinally track the occurrences of thousands of different types of health events in
millions of patients. Given two health events e1 and e2 (e.g. sepsis and ischemic
stroke), we consider the challenge of using a claims database to determine whether
e1 causes e2.
Standard approaches to this problem estimate a confidence interval for the strength
of association between occurrences of e1 and later occurrences of e2 adjusting for a
set of possible confounding variables. A confidence interval excluding the value cor-
responding to no association constitutes evidence for a causal relationship. Many
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combinations of study designs (e.g. cohort, self controlled case series, etc.) and
statistical methods (e.g. propensity score matching, regression, etc.) are available
to estimate the confidence interval for the covariate adjusted association, but for
causal validity they all require an ignorability assumption to hold (Rosenbaum
and Rubin, 1983). The ignorability assumption approximately states that there is
no confounding conditional on the covariates included in the analysis. While it is
impossible to test statistically whether ignorability holds for any particular study,
past empirical experiments on data of this form (Madigan et al., 2014) suggest
that it is the norm for failures of ignorability to be present and to lead to serious
bias.
Valid causal discovery methods do exist, however, that do not assume ignora-
bility. For example, building on earlier work by Richardson and Spirtes on Partial
Ancestral Graphs (Richardson and Spirtes, 2002), Michael Eichler has developed
a graphical model based framework for causal discovery in time series (Eichler,
2005; Eichler, 2007; Eichler, 2010; Eichler, 2012) in which it is sometimes possible
to identify relationships between pairs of time series variables as causal or spurious
without assuming that there are no unobserved confounders.
Eichler considered a situation in which we observe a subset of time series vari-
ables O from a larger stationary process V . V is assumed to be sufficiently rich
that, were we able to observe the full process, we could infer its causal structure
from the conditional temporal associations between its variables. Note that not
only do we not observe the variables in V\O, but we may not even know what
they are. For example, in our setting, O comprises a set of binary time series cor-
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responding to the daily occurrence or non-occurrence of health events that appear
in insurance claims records. We observe one realization of O for each patient. V
would contain additional unobserved variables that are sufficient to causally ex-
plain the unfolding of patients’ health histories–e.g. variables pertaining to diet
or employment status. Clearly, V may be vast. Eichler’s framework also requires
that the data generating process for V belong to a wide class of processes that
Eichler did not fully characterize but which includes, for example, all autoregres-
sive models (Eichler, 2012).
We are particularly interested in e1, e2 ∈ O. Eichler’s insight was that certain
configurations of conditional Granger non-causality (CGnC) relationships among
O are only consistent with data generating processes for V in which certain pairs of
observed variables are causally related (or spuriously associated). (A detailed defi-
nition of ‘conditional Granger non-causality’ will come later, but for now it suffices
to think of it as a form of conditional independence for time series.) Thus, under
certain assumptions about V mentioned above, there are certain sets of CGnC
relations among O that, if they held, would imply e1 causes e2. Crucially, note
that we need not assume that there are no latent common causes of variables in O.
If the CGnC relations of a process O imply that a time directed association be-
tween a pair of variables is causal (or spurious), then we say that O resolves the
association. Supposing that occurrences of e1 are associated with later occurrences
of e2, an obvious strategy to evaluate whether e1 actually causes e2 is to search
for a subset O that resolves their association. For large subsets O, many CGnC
tests are required to determine whether O resolves a given association. This is
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problematic because (a) each CGnC test requires fitting a separate model; and
(b) each individual CGnC test is prone to error, and an error in any one test may
lead to faulty causal conclusions. Therefore, it seems wise to limit the search to
smaller subsets. And because even causal conclusions derived from small subsets
are not necessarily reliable, it seems wise to search for as many resolving subsets
as possible to see if they produce a consensus.
We propose to select an ensemble of promising small subsets O1, . . . ,OR, each
containing only three variables including the pair of interest. We will describe
later how to find promising Oi. For each Oi, we learn its CGnC relations (which
can be represented by a Granger causal graph), and we tally the conclusions of
all the resolving subsets. If the resolving subsets produce a consensus that the
association is causal (spurious), we regard that as strong evidence of causality
(spurious association). If, as will often be the case, there is no consensus one
way or the other, we consider this to be an absence of evidence but not necessarily
evidence of absence. We call this procedure Ensemble of Granger Graphs, or EGG.
The hope is that a causal discovery method that does not rely on ignorability
will have higher positive predictive value than standard methods that are sensi-
tive to confounding. The price for ignoring ignorability is assuming restrictions
on the full data generating process that are required for the theoretical validity
of Eichler’s framework. Whether this tradeoff is worthwhile, and whether EGG
is robust to the violations of its assumptions that inevitably exist in practice, are
empirical questions that we begin to address in this chapter. In Section 2, we ex-
plain Granger causal graphical models and dynamic Maximum Ancestral Graphs,
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which are the tools Eichler developed for drawing limited causal conclusions from
CGnC relations in the possible presence of latent confounding. In Section 3, we
describe EGG in detail. In particular, we discuss our approach to CGnC testing.
In Section 4, we present a simulation study in which EGG demonstrates excellent
power and positive predictive value in the presence of unobserved confounding. In
Section 5, we present results from applying EGG to a collection of health event
pairs whose true (non-)causal relationships are known. EGG again demonstrates
decent power and superior positive predictive value compared to a cohort method.
We also apply EGG to two actual problems of interest in stroke research. In Sec-
tion 6, we conclude.
2.2 Granger Causal Graphical Models
Here we briefly summarize Eichler’s Granger graphical model framework for causal
discovery from time series in the presence of confounding. A longer summary can
be found in (Eichler, 2012) with further details in the references therein. In sec-
tion 2.1, we consider the interpretation of Granger causal graphical models in the
simpler context where we observe the full process and there are no unobserved
confounders. Then we look at the case where we only observe a subset of the full
process and latent confounding is possible. Throughout, we assume a structural
equations framework that is more restrictive than strictly necessary.
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2.2.1 Granger Causal Graphical Models For A Full Process
Suppose V = (V1, . . . , VM) is a stationary multivariate time series process. Further
suppose that the data generating process of V is defined by the structural equations
Vi(t) = fi(V
t−1





i ∈ {1, . . . ,M}
(2.1)
where Vi(t) denotes the value of variable i at time t, V t−1j denotes the entire history
of variable Vj through time t−1, and U ti is an error term representing the history of
influential but unobserved variables not included in V through time t. We assume
the underlying system is deterministic, though fi is not necessarily known, but we
can still speak about the probability distribution of Vi(t) because U ti is unobserved.
Given such a system, we define two notions of causality and examine their re-
lation to each other.
Definition 1 Variable Vi directly structurally causes variable Vj if and only
if fj is not constant in V t−1i .
The interpretation of direct structural causality is that one could in theory
control the distribution of a variable by intervening on its direct structural causes.
It is usually the goal of causal discovery to identify exactly such relationships.
Another popular concept of causality is conditional Granger (non-)causality. Vi is
said to be Granger non-causal for Vj relative to S ⊆ V if the history of Vi does not
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help to predict the next value of Vj given the histories of S\Vi and Vj. The special
case where S = V is often referred to plainly as Granger (non-)causality. A more
formal definition is below:
Definition 2 Given two variables Vi, Vj ∈ V, we say that Vi is Granger non-
causal for Vj relative to S ⊆ V (denoted Vi 9GC Vj|S) if Vj(t) ⊥ V t−1i |(S\Vi)t−1, V t−1j .
Otherwise, Vi is Granger causal for Vj relative to S (denoted Vi →GC Vj|S).
Unlike direct structural causality, Granger causality does not have an imme-
diate interpretation in terms of interventions, but it is easier to check empirically
without access to the underlying structural equations. The question arises of when
the two notions coincide. To address this question, we might consider two graphs
representing relationships among the variables {V1, . . . , VM} in V–the direct struc-
tural causality graph GDSCV with an edge Vi → Vj whenever Vi directly structurally
causes Vj, and the Granger causality graph GGCV with an edge Vi → Vj whenever
Vi →GC Vj|V . Note that both graphs are directed and may contain cycles. We can
then ask under what conditions the two graphs agree.
Suppose Vi does not directly structurally cause Vj, but there exists a latent com-
mon cause L /∈ V of Vi and Vj such that L(t − 2) influences Vi(t − 1) and Vj(t).
Then Vi(t− 1) and Vj(t) would be associated even after adjusting for all variables
in V , i.e. Vi would Granger cause Vj. So it is clear that for there to be any hope
of Granger causality agreeing with direct structural causality, external common
causes cannot be allowed. To enforce that no association between variables in V is
due to a common cause not included in V , we assume the following independence
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condition involving the error terms:
Ui(t) ⊥ V tj |V ti , U tj
∀i, j ∈ {1, . . . ,M}.
(2.2)
The absence of external common causes is the sense in which we can consider V to
be a ‘full’ process. However, see (Robins and Richardson, 2013) for an explanation
of how assumptions about independent errors can have subtle implications beyond
the absence of external common causes.
It turns out that for processes V meeting our assumption (2), Granger causal-
ity implies direct structural causality (White and Lu, 2010).
Proposition 1 (White and Lu, 2010) Suppose Vi, Vj ∈ V where V is generated
by structural equations (1) and has error terms satisfying the independence as-
sumption in (2). Then if Vj does not directly structurally cause Vi, Vi(t) ⊥
V t−1j |(V\Vj)t−1.
By Proposition 1, every edge in GGCV must also be present in GDSCV . Eichler and
Didilez (2010) proved a partial converse to Proposition 1 under further assumptions
on V . Eichler and Didilez make the following two technical assumptions:
The conditional distribution of V(t+ 1) given V t is almost surely absolutely




For all subprocesses A,B, C ⊆ V ,A and B are measurably separated conditional on C.
(2.4)
These assumptions are satisfied by a wide class of time series models including
all autoregressive models. Under these assumptions, Eichler and Didilez prove:
Proposition 2 (Eichler and Didilez, 2010) For variables Vi, Vj ∈ V,
(A) if there is a causal effect of intervening in Vi(t) on Vj(t+ 1), then Vi → Vj ∈
GGCV ;
(B) if there is a causal effect of intervening in Vi(t) on Vj(t + h) for any h, then
there is a directed path Vi → · · · → Vj in GGCV .
Proposition 2 is almost a converse to Proposition 1 but not quite. Proposition
2 is framed in terms of effects of interventions whereas Proposition 1 is framed in
terms of direct structural causality. It is possible, for example, for variable V1’s
value at time t− 2 to directly structurally cause V2 at time t but for the effect of
intervening on V1(t− 2) to be exactly canceled out by an indirect effect that runs
through a third variable V3’s value at time t − 1. Under the further assumption
that no direct structural causal effects are exactly canceled out by indirect effects
(often referred to as a faithfulness assumption in the graphical model literature),
Proposition 1 and Proposition 2 together imply that GDSCV and GGCV are identical.
To summarize, for a full process V that satisfies the faithfulness assumption and
technical conditions that are not terribly restrictive, Granger causality corresponds
to direct structural causality and the graph GGCV of Granger causality relations
amongst the variables is identical to the graph GDSCV of direct structural causality
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relations amongst the variables. Since it is feasible to evaluate Granger causality
empirically, these results imply that it is a useful tool for causal discovery when
we observe a full process. Of course, we rarely get to observe a full process. In the
next subsection, we discuss what conclusions may be drawn if we observe only a
subset of a full process.
2.2.2 Granger Causal Graphical Models For Processes That
May Contain Latent Variables
Let V be a multivariate time series process satisfying all the assumptions from the
previous section, and suppose that we only get to observe O ⊂ V . We may not
even know how many variables are in V\O.
Eichler showed that all conditional Granger non-causality relationships amongst
variables in V (i.e. relations of the form Vj 9GC Vi|S for any S ⊆ V) can be
derived from the structure of GGCV using a path criterion called m-separation. For
details on m-separation, consult (Eichler, 2012). To graphically represent the con-
ditional Granger non-causality relations among just the variables in O, Eichler had
to develop a new type of graph (called a dynamic Maximal Ancestral Graph or
dMAG) with two additional arrow types and a new accompanying heuristic rule
called m*-separation. A dMAG over variables O = {O1, ..., OK} consists of edges
60
of the form:
Oi → Oj, (2.5)
Oi Oj, and (2.6)
Oi −−−Oj (2.7)
Again, see (Eichler, 2012) for more details. One necessary shortcoming of
dMAGs is that, unlike Granger causal graphs for full processes, different dMAGs
may represent the conditional Granger non-causality relations of the same process.
The class of all dMAGs representing a set of CGnC relations is called a Markov
equivalence class. We say that the set of all dMAGs representing the CGnC rela-
tions of a process O is the Markov equivalence class for O. dMAGs have several
properties that make them useful tools for causal discovery. First, all dMAGs in
the same Markov equivalence class have the same skeleton, which means that they
have dashed line edges like (7) in all the same places and they have arrows in all
the same places and pointing in the same direction though the tails of the arrows
may differ in type across the Markov equivalence class between (5) and (6). This
skeleton can be learned empirically from data with conditional independence tests.
Second, given GGCV , it is possible to construct a dMAG over O (call it dMAGV(O))
such that Oi → Oj ∈ dMAGV(O) if and only if Oi → · · · → Oj ∈ GGCV . In other
words, it is always possible to construct a dMAG over an observed subset that
preserves the ancestral causal relationships from the full process in the form of
solid arrows of type (5).
Thus, if we are presented with a set of variables O that we are willing to assume
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is a subset of an unknown full process VTRUE satisfying the assumptions from the
previous section, we can use the properties of dMAGs to reason as follows. There
exists a dMAG (which we call dMAGVTRUE(O)) representing the CGnC relations
in O such that every arrow of type (5) in dMAGVTRUE(O) corresponds to a true
ancestral causal relationship in VTRUE. Therefore, if an arrow of type (5) appears
in every dMAG in the Markov equivalence class for O, it must in particular be
present in dMAGVTRUE(O) and indicate a true ancestral causal relationship. Sim-
ilarly, if every dMAG in the Markov equivalence class for O contains an arrow of
type (6), then in particular dMAGVTRUE(O) must contain the arrow of type (6),
which implies that the variable at the tail of the arrow is not an ancestral cause
of the variable at the head. This reasoning is diagrammed in Figure 1.
The entire Markov equivalence class of O can in theory be learned empirically
from data and the unanimous arrows systematically identified. However, this is
unnecessary as Eichler described simple sufficient conditions for concluding that a
→ (or ) is present in every dMAG in an equivalence class. Here we describe a
simplified version of these conditions for the case where O contains three variables.
Certain complications arise with four or more variables (Section 6 of Eichler, 2012),
but in our proposed procedure we never fit graphs with more than three variables.
First, the skeleton for a three variable process can be learned as follows. If
Oi →GC Oj|O and Oi →GC Oj|∅, then the skeleton of the Markov equivalence
class for O contains Oi Oj (where ‘ ’ denotes an arrow whose tail may be of
type (5) or (6)).
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Figure 2.1: In the top row are the are infinitely many full processes that could have
produced the observed CGnC relations CGnC(O). Each of them has ancestral
causal relations corresponding to the solid arrows in one of the n dMAGs in the
Markov equivalence class representing O in the bottom row. dMAGV (O) has solid
arrows corresponding to the ancestral causal relationships in the true full process
V . The lines in the diagram from the top row to the bottom row connect processes
to their corresponding dMAGs. Any solid arrow present in every dMAG in the
bottom row is in particular in dMAGV(O) and therefore in True V .
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Proposition 3 If a skeleton for O = {O1, O2, O3} contains O1 O2 O3 but not
O1 O3, then it is possible to determine whether O2 causes O3 or the association
is spurious. If O1 →GC O3|∅ but O1 9GC O3|O2, then O2 → O3 must be in every
dMAG in the Markov equivalence class for O and therefore O2 must cause O3. If
O1 9GC O3|∅, then O2 O3 must be in every dMAG in the Markov equivalence
class for O and therefore the association between O2 and O3 must be spurious.
The intuition behind this result is that causal effects pass temporal associations
forward in time. Therefore, it should be necessary to condition on a cause to block
the association between its precursor and its effect. Spurious associations do not
carry associations forward in time, and it should not be necessary to condition on
a spurious cause in order to block the association between its precursor and its
spurious effect.
2.3 Ensembles of Granger Graphs (EGG)
We explain our proposed procedure in the context of a large longitudinal database
of health histories, though it should be obvious how it would extend to other similar
situations, e.g. simultaneous observations of large numbers of neural spike trains.
Suppose there are P patients indexed by p ∈ {1, . . . , P}, and the pth patient is
observed for Np days. In each patient, the same M health events {e1, . . . , eM} are
monitored. The pth patient’s history comprises a collection of binary time series
{ep1, . . . , e
p
M} documenting the occurrence or non-occurrence of each health event
on each day. epi is a vector of dimension Np such that e
p
i (t) = 1 if event ei occurred
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on day t to patient p and 0 otherwise.
Suppose that in our P observations of {ep1, . . . , e
p
M}, we have detected a large
association between occurrences of health event ei and later occurrences in the
same patient of ej. For example, ei may be ischemic stroke and ej may be paraly-
sis. To address the question, ‘Does ei actually cause ej?’, we propose learning an
ensemble of dMAGs containing ei and ej. The procedure has three general steps:
Step 1. Select a set of candidate subprocesses {O1, . . . ,OR}, each containing
ei and ej, that are likely to resolve the association between ei and ej.
Step 2. For each Ok, conduct a series of conditional Granger causality tests to
learn the skeleton of the Markov equivalence class for Ok and, if Ok resolves the
association between ei and ej, determine the causal implications of Ok.
Step 3. Tally the results and summarize the evidence across subprocesses.
There are many options for how to perform each step of this general procedure.
Below we discuss some of the considerations involved in each step and describe the
choices we made in our experiments.
2.3.1 Step 1: Selecting Subprocesses
We prefer to use small subprocesses with just one variable in addition to ei and
ej. This is because the number of conditional Granger causality tests required for
each process in Step 2 increases quickly with the number of variables. Therefore,
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large processes will be both computationally expensive and unreliable. The reason
more conditional Granger causality tests implies less reliability is that an error in
any single test can alter the direction of evidence supplied by a process.
We want to choose subprocesses O = {eh, ei, ej} that are likely to resolve the as-
sociation of interest between ei and ej. Proposition 3 suggests that this amounts
to choosing variables eh that Granger cause ei both conditional on the empty set
and on ej. This way, eh ei will be in the skeleton. Given that ei and ej were
found to be associated in a prior adjusted analysis, ei ej will also likely be in
the skeleton. So by Proposition 3, all that’s needed for O to resolve the association
is for eh to be Granger non-causal for ej conditional on ∅ or ei.
We would further like to choose subprocesses that have low probability of re-
solving the association incorrectly due to statistical errors. There are two ways
in which our procedure might go wrong for a given subprocess. ei could be only
spuriously associated with ej but the subprocess could resolve it as causal (call
this a type 1 error), or vice versa (a type 2 error).
Type 1 errors occur when we are able to detect that eh →GC ej|∅ but not that
eh →GC ej|ei. (See Proposition 3.) This is likely to happen when the association
between eh and ei is very strong and there are not enough instances of eh occurring
without being followed by ei to provide sufficient power to detect that eh predicts
ej conditional on ei. We can reduce the chances of type 1 error by requiring that
eh has prevalence above some threshold in the data and is at least occasionally
not followed by ei.
66
Type 2 errors occur when we fail to detect that eh →GC ej|∅ even though ei
causes ej. This is likely to happen if the unadjusted association between eh and
ei is weak or if the causal effect of ei on ej is weak. This is because the only
association guaranteed to exist between eh and ej is the indirect combination of
the association between eh and ei and the causal effect of ei on ej. This indirect
association will be weaker than either of its component parts. We of course cannot
control the strength of the causal effect of ei on ej, but we can require that the
strength of the unadjusted association between eh and ei is above some minimum
threshold. We can also again require that the prevalence of eh is above a minimum
threshold. Together, these requirements would ensure that there is sufficient power
to detect an association between eh and ej as long as the causal effect of ei on ej
is not extremely weak.
In practice, we collect promising candidates for the role of precursor variable eh
as follows. First, we decide the maximum number R of variables to select. (In our
experiments in Section 5, we set R = 50.) We then define a measure of unadjusted
strength of temporal association to be used for screening. In our experiments,
we used a crude ‘reverse incidence ratio’ for this purpose. Specifically, we defined
all days preceding an occurrence of ei to be ‘exposed’ and all other days to be
unexposed, then took
[(#eh occurrences on exposed days)/(# exposed days)]/
[(#eh occurrences on unexposed days)/(# unexposed days)]
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to be the strength of temporal association between eh and ei. This measure rewards
events eh that disproportionately precede ei. Next, we search the dataset for all
variables that exceed some minimum allowable unadjusted strength of association
with ei (reverse incidence ratio > 2 in our experiments) and some minimum allow-
able population prevalence (.001 in our experiments). These minimum thresholds
are chosen dependent on sample size to ensure sufficient power for relevant Granger
causality tests. In our database, it was possible to quickly compute incidence ratios
and prevalences for thousands of candidate variables using a few SQL commands.
We then exclude any variables that only rarely occur without being followed by ei,
and if there are more than R variables remaining we select the R with the highest
incidence ratios.
2.3.2 Step 2: Conditional Granger Causality Testing
As described in Section 2.2, learning the skeleton of a Granger causal dMAG for
process O = {O1, O2, O3} and hopefully identifying one of its arrows consists of
performing a series of conditional Granger causality tests. There has been work on
nonparametric conditional Granger causality testing (Diks and Panchenko, 2005;
Su and White, 2008; Dhamala et al., 2008), but existing methods are still slow and
lack power, particularly for binary data. We therefore employ model based tests.
To test whether variable O2 is Granger causal for variable O3 conditional on vari-
able S (where S could be O1 or the empty set), we fit two models for O3–one which
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incorporates information from the histories of S, O2, and O3 (call this modelMS,2)
and one which only incorporates information from the histories of S and O3 (call
this model MS). We assign prior probability of 1/2 to each model and compute
each model’s posterior probability given the data. If P (MS,2|Data) > 1 − δ for
some δ, we declare Granger causality. If P (MS,2|Data) < δ, we declare Granger
non-causality.
We use simple piecewise constant conditional intensity models (PCIMs) for MS,2
andMS. See (Gunawardana et al, 2011) for a more complete discussion of PCIMs.
A PCIM for the process O comprises a set of ‘structures’ A = {A1, A2, A3} and
parameters λ. The structure Ai is a set of discrete ‘states’ that the history of O
may satisfy at any given time. For example, a simple structure with states that
incorporate the histories of all three variables might contain one state for each
of the 8 possible combinations of binary indicators for past occurrences of each
variable. Or structures could be richer, including states defined by how long ago
each variable occurred or the number of times each variable has occurred. For
each state a ∈ Ai, there is a corresponding conditional intensity λia which is the
probability of Oi occurring on any day satisfying a. Let x represent realizations of










where cia(x) denotes the number of times that Oi occurs in x under state a and
dia denotes the total number of days that x is in state a.
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The conjugate posteriors for the conditional intensity parameters are then
p(λia|αia, βia, x) = p(λia|αia + cia(x), βia + dia(x)) (2.10)













Returning to our example where we want to evaluate whether O2 Granger causes
O3 relative to OS, let MS,2 and MS be two PCIMs for O with the same structures
A1 and A2 but different A3. Because the marginal likelihood for a PCIM factors
by variable, the Bayes factor comparing MS,2 and MS will be the ratio of the third














In our experiments and simulations, we set the hyper parameters α and β both
equal to 1 for all variables and states, so that the Bayes factor is dominated by
the likelihood. We used simple structures for AS,23 and AS3 . If S = O1, AS3 con-
tains one state for each of the 4 possible combinations of binary indicators for past
occurrences of O1 and O3, and AS,23 contains one state for each of the 8 possible
combinations of binary indicators for past occurrences of O1, O2 and O3. If S is
the empty set, AS3 contains just two states: one corresponding to a past occurrence
of O3 and one corresponding to no past occurrence of O3. And AS,23 would contain
the 4 states corresponding to the different combinations of past occurrences of O2
and O3. Of course, it is clear how to modify the above for any choice of variables
to be the Granger cause, Granger effect, and conditioning variable.
In our claims data experiments, we performed all conditional Granger causal-
ity tests only on subpopulations of patients in whom the potential Granger effect
occurred. Thus, we required a Granger cause to predict the timing of a Granger
effect in patients who had the Granger effect at some time. This requirement im-
plicitly adjusts conditional Granger causality tests for baseline confounders that
impact the probability of occurrence of the Granger cause and Granger effect but
do not impact their relative timing.1
1This adjustment was necessary because when we applied our test to the full population, con-
ditional Granger non-causality was extremely rare. Every health event was temporally associated
with every other health event conditional on at most one additional health event. The reason
appeared to be that some patients generally had many more conditions of all types than other
patients, i.e. some patients were frailer at baseline than others. This led to associations between
all conditions because occurrence of any given condition was more likely in a frail patient, and
such patients in turn were more likely to have other conditions in their records. Restricting
Granger causality tests to subpopulations who at some time had the potential Granger effect
made conditional Granger non-causality much more common.
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Any causal conclusion from O rests on multiple conditional Granger causality
tests. To conclude that O implies that O2 causes O3, recall that the following
conditional Granger causality relations must hold:
O1 →GC O2|∅ (2.14)
O1 →GC O2|O3 (2.15)
O2 →GC O3|∅ (2.16)
O2 →GC O3|O1 (2.17)
O1 →GC O3|∅ (2.18)
O1 9GC O3|O2 (2.19)
And to say that O implies that O2 is just spuriously associated with O3, recall
that in addition to (14)-(17) above, the following conditional Granger non-causality
relation must hold:
O1 9GC O3|∅ (2.20)
In our experiments, to be conservative in avoiding causal errors, we set δ = .001.
Thus we required that the posterior probability of any model favoring Granger
causality be greater than .999 in order to declare Granger causality or less than
.001 in order to declare Granger non-causality.
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2.3.3 Step 3: Tallying the Results
The output of EGG comprises the causal implications of 50 subprocesses. Most
subprocesses do not resolve the association of interest. Say Q subprocesses are
resolving, T point to a real association, and F point to a spurious association. A
convenient summary statistic of the strength of evidence about the causal nature
of the association between events ei and ej is P* as defined below:
If ei →GC ej|∅ and ei →GC ej|eh, P*(ei, ej) =
T + 1
T + F + 2
Otherwise, P* = 0.
(2.21)
If Q > 0 and T ∼ Binomial(Q, p), P* would be the posterior mean of p assuming
a Beta(1, 1) prior. Higher values of P*(ei,ej) tend to support causality, and lower
values tend to support spurious association. P* is not the posterior probability of
causation, however. It is not even reasonable to assume that T ∼ Binomial(Q, p)
because the conclusions of various subprocesses are not necessarily independent.
P* is just a convenient way to compare the strength of evidence from EGG out-
puts for different event pairs that have different numbers of resolving subprocesses.
Because the distribution of P* is impossible to reliably determine theoretically
due to inevitable model misspecification, we recommend constructing empirical
distributions of true negative controls and true positives for testing (Schuemie et
al, 2013). For example, to evaluate whether stroke causes paralysis, one could
first find a collection of true negative conditions {eTN1 , . . . , eTNV } that stroke does
not cause but does tend to precede and apply EGG to each of these to obtain
{P*(stroke, eTN1 ), . . . , P*(stroke, eTNV )}. One could similarly collect a a group of
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true positive conditions that stroke does cause, apply EGG to these, and obtain
{P*(stroke, eTP1 ), . . . , P*(stroke, eTPV ′ )}. Finally, compare P*(stroke, paralysis)
to the distributions of true negatives and true positives to assess the probability
that it comes from the true positive distribution.
2.3.4 A Real Example: Ischemic Stroke and Paralysis
We collected 50 precursors of stroke meeting the criteria laid out in Section 3.1.
For each precursor eh, we performed a series of conditional Granger causality tests
on the subprocess {eh, stroke, paralysis} as described in Section 3.2. 9 out of the
50 subprocesses resolved the association between stroke and paralysis, and 8 of the
9 implied causality (P*=.82). That is, there were 8 precursors of stroke that were
temporally associated with paralysis but almost entirely through stroke, providing
strong evidence that stroke causes paralysis. We then computed P*(stroke,X)
for multiple conditions X that tend to follow stroke and are either known to be
caused by stroke or known not to be caused by stroke. P*(stroke,paralysis) was
firmly in the distribution of P* values for the true positives and separated from
the distribution of P* values for the true negatives.
2.4 A Simulation
In this section, we describe the results of applying EGG to simulated longitudinal
data with unobserved confounding. The simulation setup was meant to resemble
the structure of a health history, though of course it was vastly less complex.
We generated 10,000 simulated patient records, each observed for 50 ‘days’ and
monitored for 100 ‘conditions’. Each condition was caused by two other randomly
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selected conditions and was only allowed to occur once. (The restriction to a single
occurrence was meant to mimic the common practice when working with claims
data of only counting the first occurrences of events. This practice is in response to
the fact that subsequent appearances of an event in a patient record are likely to be
billing artifacts that do not actually correspond to new occurrences.) A diagram
of the causal connections between conditions is in Figure 2 below. When a cause
occurs for the first time, it increases the probability of its effect occurring by a
constant amount for each day afterwards, until the effect occurs at which point its
probability of occurring again drops to 0. The probability of event j occurring in
patient p at time t was given by
P (epj(t) = 1|H t−1p ) =logit−1(−4 + 2max(ct−1pj1 ) + 2max(ct−1pj2 )), if max(et−1pj ) = 0;
0, otherwise
(2.22)
where ct−1pji represents the history of the ith cause of condition j in patient p through
time t− 1.
We identified a set of conditions that were linked by common direct causes, and
therefore fairly strongly associated, but were not connected to each other by any
directed path in the causal diagram. The associations between these conditions
were purely spurious. We then dropped the common causes from the dataset so
that we were left with 28 condition pairs associated due to unobserved confound-
ing. Since the temporal association went in both directions for these confounded
pairs, we arbitrarily assigned one condition in each pair to be a potential cause and
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the other to be a potential effect. We then applied EGG to these 28 true negative
pairs and to 50 additional true positive pairs that were directly causally linked.
Figure 2.2: A causal graph of the 100 ‘conditions’ in our simulated health records
2.4.1 Selecting Subprocesses
We screened for candidate precursors using logistic regression. For each potential
cause ec, for each potential precursor eb (i.e. every condition other than ec), we fit
the logistic regression
epc(t) ∼ max(et−1pb ) +max(e
t−1
pc ) (2.23)
For each pair {ec, ed}, where ed is the potential effect, we then collected the 10 po-
tential precursors {precc1, . . . , precc10} with p-values less than .01 that had largest
logistic regression coefficients predicting ec and formed subprocesses {O1, . . . ,O10} =
{{precc1, ec, ed}, . . . , {precc10, ec, ed}}.
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2.4.2 Conditional Granger Causality Testing
We performed a modified version of the conditional Granger causality tests de-
scribed in section 3.2 without restricting to the subpopulation in which the po-
tential Granger effect occurs. It was necessary to modify the test because our
process was not stationary. (The value of each variable at time t depends on
the entire histories of its two causes, and the length of those histories varies with
t.) Stationarity is a technical requirement for the validity of Eichler’s framework.
Without stationarity, the history of a variable that is not at all linked to another
variable in the causal network (i.e not linked through a directed path or through
a common ancestral cause) can nonetheless carry predictive information by act-
ing as a rough clock indicating the likely value of t. To address this problem, in
each PCIM we included an additional binary predictor process indicating whether
t > 15. We chose 15 because that was near the mode of the distribution of first
event times. Conditioning on this additional variable prevented the conditional
Granger causality tests from picking up extraneous dependencies unrelated to the
causal network.
2.4.3 Results
There was striking separation between the values of P* for the true negatives and
the true positives. While the procedure occasionally drew incorrect conclusions
from individual subprocesses, the ensemble was never badly fooled by unobserved
confounding and had good power to detect real causal effects relative to the empir-
ical null distribution. Note that any standard method assuming ignorability would
identify every true negative (along with every true positive) as a causal relation-
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ship in this setup. Also note that this simulation demonstrates some robustness
to violations of stationarity of the full process. The R code for these simulations
is available at zshahn.columbia.edu.
Figure 2.3: Output from applying EGG to 50 true causal effects and 28 spurious
associations in simulated data
2.5 Experiments With Claims Data
We explored the performance of EGG on several problems in a real medical claims
database. We evaluated EGG’s ability to separate (a) effects from non-effects of
ischemic stroke; (b) causes from non-causes of ischemic stroke; and (c) drugs for
which acute renal failure is a side effect from drugs for which acute renal failure
is not a side effect. Using the empirical distributions generated in (b), we applied
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EGG to two questions of genuine interest in stroke research: (1) Does sepsis cause
ischemic stroke?; and (2) Does sleep apnea cause ischemic stroke? We compared
the performance of EGG on all of these problems to a high dimensional inverse
propensity weighted cohort method.
All applications were performed in the Thomson Reuters MarketScan Lab Database
(MSLR) which contained approximately 8 million patients. The database was con-
verted to the OHDSI Common Data Model (CDM) (Stang et al., 2010). We defined
conditions by mapping their ICD-9 codes to the corresponding concept IDs in the
CDM. Unfortunately, it was beyond the scope of this project to implement more
complex and better validated definitions for each condition. We included only the
first occurrence of any condition in a health record. The reason is that repeat
occurrences tend to be artifacts of billing practices that do not represent actual
reoccurrences of the health event.
2.5.1 Effects of Ischemic Stroke
We compiled a list of conditions that were strongly predicted by ischemic stroke
(incidence ratio > 2) in univariate analyses and occurred at least 25,000 times in
our data. Working with a stroke neurologist, we identified a subset of these stroke
successors that are definitely caused by stroke and a subset that are definitely not
caused by stroke. The incidence ratios of the true positives were mostly higher
than the incidence ratios of the true negatives. For each true positive and true
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negative condition we identified, we applied EGG to test whether it was caused by
stroke, proceeding as described in Section 3. Examples of stroke precursors that
our algorithm selected are brain neoplasm, cerebral ischemia, carotid artery ob-
struction, dementia, Alzheimer’s disease, Parkinson’s disease, heart failure, kidney
failure, hemiplegia, and atrial fibrillation. The separation of P* between true posi-
tives and true negatives was striking, similar to the results of the simulation study.
The full output including numbers of resolving subprocesses implying causality and
spurious association is in the appendix.
Figure 2.4: Output from applying EGG to 18 true effects and 14 spurious succes-
sors of ischemic stroke
2.5.2 Causes of Ischemic Stroke
We compiled a list of conditions that strongly predicted ischemic stroke (incidence
ratio > 2) in univariate analyses in our data. Working with a stroke neurologist,
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we identified a subset of these stroke precursors that definitely cause stroke and a
subset that definitely do not cause stroke. The distribution of incidence ratios was
similar in the true positive and true negative groups, with the lowest few incidence
ratios actually being true positives. For each true positive and true negative con-
dition we identified, we applied EGG to test whether it causes stroke, proceeding
as described in Section 3. The separation is not as good for this application as
for the effects of stroke. This may be because causal effects are weaker and re-
sponsible for a smaller proportion of outcome occurrences. Still, EGG produced
stronger evidence of causality for 6 of the 13 true positives than any of the 19 true
negatives. This was far superior to the comparator cohort method, as we will see
later.
Figure 2.5: Output from applying EGG to 13 true causes and 19 spurious precur-
sors of ischemic stroke
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2.5.3 Two Questions of Interest
Strong temporal associations between both sepsis and sleep apnea and ischemic
stroke have been observed (Walkey et al., 2011; Yaggi et al., 2005). There are
plausible mechanisms for a causal connection in both cases, but causality is not
firmly established. Using the empirical true negative and true positive distributions
generated in Section 5.3 by the stroke precursors, we applied EGG to investigate
whether sepsis or sleep apnea cause ischemic stroke.
For sepsis, 8 of 50 subprocesses resolved the association, and all 8 implied a causal
relationship (P*=.9). This was much stronger evidence for causality than any of
the 19 true negatives (or true positives). These results say that there are many
conditions that tend to precede sepsis and are only associated with ischemic stroke
through sepsis. This is strong evidence for causality.
But taking a look at the CDM concept names of the 8 resolving precursors may
reduce the strength of our conclusion. Those concept names are: ‘Osteomyelitis of
ankle AND/OR foot’, ‘Gangrenous disorder’, ‘Infection AND/OR inflammatory
reaction’, ‘ulcer of heel’, ‘ulcer of knee’, ‘Esophageal varices without bleeding’,
‘Osteomyelitis’, and ‘Ulcer of lower limb’. While these are all technically distinct
concepts in our data, it seems silly to count some of them as separate precur-
sors offering independent sources of evidence. For example, ‘Osteomyelitis’ and
‘Osteomyelitis of ankle AND/OR foot’ are surely very similar. As are ‘Ulcer or
lower limb’, ‘Ulcer of heel’, and ‘Ulcer of knee’. But even if sepsis only has 4 or
5 precursors identifying it as causal (and none identifying it as spurious), this is
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solid evidence for causality in light of the empirical distributions from the other
stroke precursors.
For sleep apnea, there were only 25 precursors that met our criteria for strength
of association, prevalence, and distinctness from the potential cause. Of these 25,
three resolved the association between sleep apnea and stroke, and all three implied
a causal relationship (P*=.8). This is stronger evidence of causality than EGG
produced for any of the negative controls. The three resolving precursors were
narcolepsy, movement disorder (e.g. the sleeping disorder restless leg syndrome),
and sarcoidosis.
The full output for sepsis and sleep apnea are in the appendix.
2.5.4 A Comparator Cohort Method
We also performed cohort analyses for all of the stroke examples. For each analy-
sis, we randomly selected a control cohort of the same size as the exposed cohort,
taking the index date for the control cohort to be a random hospital visit. We
then used lasso logistic regression to fit high dimensional propensity score mod-
els predicting cohort membership based on binary predictors indicating pre-index
date occurrence of every condition, drug, and procedure as well as age and gender
and a few frailty measures (total pre-index date conditions, drugs, and hospital
visits). We used the estimated propensity scores to fit inverse propensity score
weighted cox survival models for the outcome with cohort as the predictor. For
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stability, as is common practice, we trimmed the data to only include observations
with propensity scores between .05 and .95.
The cohort method had very poor positive predictive value as typically applied.
With p-value less than .01 as the criterion for causality, the cohort comparator
detected a causal effect for every condition that definitely did not cause stroke
and 13 of the 14 conditions that stroke definitely did not cause. (Recall that all
the negative controls were chosen to be very strongly associated with stroke in
unadjusted analyses.)
We also looked at whether there was separation in the empirical distributions of
estimated adjusted hazard ratios between true positives and true negatives. There
was no separation between causes and non-causes of stroke.
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Figure 2.6: Adjusted log hazard ratios of 13 true causes and 19 spurious precursors
of ischemic stroke
There was much better separation for effects and non-effects of stroke, but there
was also some separation in the unadjusted incidence ratios. The cohort method
did not distinguish well between the true positives and true negatives with similar
unadjusted incidence ratios, leading to some overlap between the two distributions
where EGG had none (see Figure 4).
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Figure 2.7: Adjusted log hazard ratios of 18 true effects and 14 spurious successors
of ischemic stroke
2.5.5 Drug Side Effects
In a series of empirical experiments (called the OMOP experiments), a group of
researchers recently evaluated the performance of many standard epidemiological
methods at detecting side effects of drugs using claims data (Madigan et al., 2014).
They found that confidence intervals for all methods had poor coverage probabil-
ity on a set of negative controls where the true effect size was thought to be zero.
Such poor coverage leads to high false positive rates and low positive predictive
value for tests based on individual analyses. When tests were based on empirical
distributions of positive and negative controls, results were mixed. For a given side
effect and database, there usually existed settings for some method that separated
the positive and negative controls very well. However, slightly different settings
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of the best separating method often led to poor separation in the same database.
And methods that separated positives and negatives well for one combination of
database and side effect often performed very poorly for other combinations.
Among the positive and negative controls considered in the OMOP experiments
were 88 drugs that were either known to cause or not to cause acute renal failure.
24 of the 88 drugs were true positives. The best performing method in the MSLR
database (an earlier version of the same database we used in this study) was a
self controlled case series approach that achieved perfect separation with an AUC
of 1. But performance was sensitive to method settings such as exposure window
as well as method type, and many standard methods had AUCs no better than
random guessing.
We applied EGG to this set of 88 drugs. EGG did not provide evidence of causality
for any drug or separate the true positives from the true negatives. EGG’s poor
power in this setting is presumably due to the fact that the true causal effects
are weak. Serious drug side effects tend to be very rare; otherwise, they would be
detected in clinical trials and the drug would not be allowed on the market. EGG
searches for associations between precursors and effects that are only transmitted
through causes. When causal effects are weak, indirect associations that are only
transmitted through the causal effects are even weaker and therefore very difficult
for our crude conditional Granger causality tests to detect. There were only 84,626
instances of acute renal failure in the (relatively small) database we were using for
our experiments, and it is possible that EGG would perform better at detecting
weak effects in a larger database.
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2.6 Discussion
The key idea behind this paper is that if it is necessary to condition on a potential
cause to block the temporal association between its precursor and a potential effect,
this can be construed as evidence of causality. Also, if a potential cause’s precursor
is unassociated with a potential effect unconditional on the potential cause, this
can be construed as evidence for spurious association. This reasoning (let us call
it ‘blockage reasoning’) is formally justified under certain assumptions by Michael
Eichler’s framework of Granger causal graphical models and dMAGs, but it is also
intuitive. True causal effects ought to ‘pass forward’ temporal associations in time,
whereas spurious associations ought not to. Whether it is necessary to condition
on a potential cause in order to block the association between its precursor and its
potential effect is an indication of whether the potential cause is ‘passing forward’
the association. Crucially, blockage reasoning cannot be derailed by unobserved
confounding alone, unlike standard epidemiological methods for causal discovery.
Hence, blockage reasoning can usefully supplement standard techniques by provid-
ing an independent evidence source susceptible to different biases (Zubizarreta et
al., 2012).
We have developed a novel causal discovery algorithm called EGG based on dy-
namic Maximal Ancestral Graphs that represent conditional Granger (non-)causality
relations. To guard against the instability of causal conclusions from individual
subprocesses (stemming from possible sensitivity to model misspecification, poor
data quality, sampling variation, or departures from technical assumptions about
the underlying data generating process), we employ ensembles. Other authors
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have applied confounding resistant causal discovery methods to longitudinal data
(Entner and Hoyer, 2010; Waldorp et al., 2011; Chu and Glymour, 2008; Eichler,
2007), but we are unaware of any prior work that searches for sets of variables (or
ensembles of such sets) to resolve specific associations of interest.
We provided some empirical evidence of EGG’s utility from a simulation and
claims data experiments in which unobserved confounding was certainly present.
Based on these initial findings, EGG appears to be robust to both unobserved
confounding and various violations of technical assumptions. Our simulation and
experiments both involved non-stationary processes, and the patients in our ex-
periments were heterogeneous at baseline. Yet we saw that EGG rarely produced
decisive false positives and had high power to detect strong causal effects. Un-
fortunately, its power does appear to diminish greatly with effect size. Of course,
much more empirical and theoretical work is needed to thoroughly explore the
operating characteristics of EGG or other methods built on similar foundations.
We also applied EGG to two questions of interest in stroke research–namely,
whether two ‘risk factors’ for stroke (sleep apnea and sepsis) are actual causes
of stroke. In medicine, the term ‘risk factor’ is often used for any predictor of a
condition, whether or not it is causal. It can be important to know whether a
risk factor is causal because treating non-causal risk factors serves no preventive
purpose. For both sleep apnea and sepsis, we compared EGG’s output to the em-
pirical distributions of its output for sets of true positive and true negative causes
of stroke. There was very strong evidence that sepsis causes stroke and weaker
but still solid evidence that sleep apnea causes stroke.
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We take ‘EGG’ to refer to the general three step process described at the be-
ginning of Section 3. In Step 1, we identify promising subprocesses containing the
variables of interest. In Step 2, we employ conditional Granger causality tests to
learn the dMAGs representing the conditional Granger causality relations among
the subprocesses generated in Step 1 and determine their causal implications (if
any). In Step 3, we tally the results of the resolving subprocesses and summarize
the evidence. There are many ways one might choose to perform each of these
steps and many opportunities to improve over the existing algorithm.
For instance, in Step 3, we count each resolving subprocess separately and equally.
But, as we saw in the case of sepsis and stroke, subprocesses may be related to
each other. If this is the case, it is inappropriate to consider them as independent
sources of evidence. We informally discounted the strength of evidence in our
analysis of sepsis, but it should be possible to address the problem more formally.
For example, one could develop a weighting scheme based on the distance between
precursors in the CDM concept hierarchy (Stang et al., 2010) and/or the empirical
associations between precursors in the data.
We also hope to explore alternative conditional Granger causality tests (e.g. tests
based on mutual information such as in Amblard and Olivier, 2011). In our simu-
lations and experiments, we made ad hoc modifications to the conditional Granger
causality tests in Step 2. Specifically, in our simulations we adjusted for time to
deal with lack of stationarity, and in our experiments on claims data we fit mod-
els only within subpopulations who experienced the potential Granger effect at
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some point in time to handle baseline confounding that impacted occurrence but
not relative timing of events. Other ad hoc modifications than those we made
may have superior operating characteristics, and it may also be possible to extend
Eichler’s framework to put EGG on stronger theoretical footing when the sorts of
violations and irregularities our modifications were aimed at are present. Also, fast
and flexible temporal dependency models for binary time series together with fast
and reliable model selection could lead to improved conditional Granger causality
tests. Improved tests could potentially allow for the use of larger dMAGs, which
could have a higher resolving rate than the 3 variable subprocesses we used and
hence increase power.
The most obvious shortcoming of EGG compared to standard methods is that
EGG does not estimate the size of causal effects. One could argue that causal dis-
covery is a misguided endeavor as in reality almost everything is causally related
to almost everything else, even if the vast majority of causal effects are tiny. In
this view, we learn little when we learn that a causal relationship merely exists,
the real question being, ‘what is its size?’. In practice, however, EGG seems to
pick up mainly causal effects that are relatively large and therefore interesting, at
least with the sample sizes and thresholds we were working with.
A related concern is that in reality conditional Granger non-causality is exceed-
ingly rare no matter how large the conditioning set. With enough data, we could
always detect dependence. If this is so, then for real problems EGG would be
anti-consistent in the sense that as sample size increases eventually no subprocess
in the ensemble would ever be resolving. However, this concern applies equally
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to every existing causal discovery method based on conditional independence con-
straints.
Another objection one might raise to this work is that our comparison to a cohort
method was unfair. The comparator cohort method that relied on ignorability for
validity fared considerably worse in our experiments, as it appeared to be consis-
tently foiled by unobserved confounding. We grant that an epidemiologist carefully
creating a custom study design and performing a sensitivity analysis for each ex-
ample would have likely performed better than our cohort method. We also note
that EGG was not carefully applied, either. In the hands of an epidemiologist,
careful selection of precursors based on subject matter knowledge might improve
performance.
The main contribution of this paper was to demonstrate that an algorithm based
on blockage reasoning could be successfully applied to high dimensional longitudi-
nal data for causal discovery and avoid some of the pitfalls related to unobserved
confounding that plague more standard methods. We made many specific choices
in constructing our particular algorithm, the use of ensembles probably being the
most important. But there are many other ways one could have proceeded. We
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2.8 Appendix A: Effects of Stroke
Conditions stroke→GC e|∅ #GnC spurious causal P* truth
altered mental 1.000 0 0 8 0.004 1
speech 1.000 0 1 15 0.000 1
lack of coordination 1.000 0 1 14 0.000 1
gait 1.000 0 0 9 0.002 1
resp failure 1.000 0 0 3 0.125 1
psychotic 1.000 0 1 6 0.062 1
septicemia 1.000 0 0 4 0.062 1
strength reduced 1.000 0 0 6 0.016 1
amnesia 1.000 0 0 9 0.002 1
venous thrombosis 1.000 0 1 4 0.188 1
ami 1.000 0 0 3 0.125 1
hip injury 1.000 0 0 3 0.125 1
pulmonary embolism 1.000 0 1 6 0.062 1
involuntary movement 1.000 0 1 6 0.062 1
bedsores 1.000 0 0 6 0.016 1
cerebral edema 1.000 0 0 20 0.000 1
paralysis 1.000 0 1 8 0.020 1
pneumonitis 1.000 0 1 9 0.011 1
cataract 0.003 1.000 0
glaucoma 1.000 14 7 0 0.992 0
spinal stenosis 0.814 0
acute renal failure 0.964 25 10 0 0.999 0
acidosis 0.000 1.000 0
kidney stage3 1.000 0 6 0 0.984 0
abdominal aneurism 0.000 1.000 0
emphysema 1.000 1 6 0 0.984 0
foot ulcer 0.000 1.000 0
diabetic polyneuropathy 0.006 1.000 0
amd 0.001 1.000 0
diabetic renal 0.000 1.000 0
hypertension 1.000 0 1 0 0.500 0
diabetic oculopathy 0.742 0
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2.9 Appendix B: EGG Output for Sleep Apnea
Precursor IR Prevalence eh →GC stroke|∅ apnea→GC stroke|eh eh →GC stroke|apnea conclusion
Narcolepsy 3.553 0.001 0.994 1.000 0.000 1
Movement disorder 2.799 0.004 1.000 1.000 0.000 1
Morbid obesity 2.776 0.035 1.000 1.000 1.000
PPHT 2.565 0.002 1.000 1.000 1.000
pulmonary heart disease 2.485 0.005 1.000 1.000 1.000
Articular gout 2.392 0.004 0.123 1.000 0.000
Respiratory observation 2.366 0.078 1.000 1.000 1.000
Hypoxaemia 2.331 0.010 1.000 1.000 1.000
Congestive cardiac failure 2.305 0.018 1.000 1.000 1.000
Acute asthmatic bronchitis 2.242 0.002 1.000 1.000 1.000
Sarcoidosis 2.151 0.002 1.000 1.000 0.000 1
Cardiomyopathy 2.135 0.010 1.000 1.000 1.000
coronary artery bypass graft 2.135 0.002 1.000 1.000 0.046
Left ventricular failure 2.134 0.003 1.000 1.000 1.000
Vaquez’s disease 2.127 0.002 1.000 1.000 1.000
Atrial fibrillation 2.121 0.019 1.000 1.000 1.000
cardiac defibrillator in situ 2.091 0.002 1.000 1.000 1.000
Atrial flutter 2.085 0.004 1.000 1.000 1.000
Hypertensive CHF 2.072 0.001 1.000 1.000 1.000
Abnormal cardiovascular 2.044 0.008 1.000 1.000 1.000
Diastolic heart failure 2.042 0.002 1.000 1.000 1.000
Neurologic disorder diabetes 2.032 0.014 1.000 1.000 1.000
Coronary arteriosclerosis 2.031 0.044 1.000 1.000 1.000
Cardiomegaly 2.030 0.020 1.000 1.000 1.000
Preinfarction syndrome 2.024 0.012 1.000 1.000 1.000
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2.10 Appendix C: EGG Output for Sepsis
Precursor IR Prevalence eh →GC stroke|∅ sepsis→GC stroke|eh eh →GC stroke|sepsis conclusion
kidney stage 5 15.812 0.001 1.000 1.000 1.000
Dialysis observation 15.458 0.001 1.000 1.000 1.000
Complication of implant 14.835 0.002 1.000 1.000 1.000
End stage renal disease 14.727 0.003 1.000 1.000 1.000
Erythroid aplasia 14.142 0.001 1.000 1.000 0.183
Anemia in neoplastic disease 13.594 0.001 1.000 1.000 1.000
Pancytopenia 13.406 0.002 1.000 1.000 1.000
hyperparathyroidism of renal origin 13.053 0.002 1.000 1.000 1.000
Anemia of chronic renal failure 12.933 0.004 1.000 1.000 1.000
Pressure sore 12.547 0.001 1.000 1.000 0.984
Liver secondary cancer 12.492 0.002 1.000 1.000 1.000
Alcoholic cirrhosis 12.082 0.001 1.000 1.000 1.000
Portal hypertension 11.945 0.001 1.000 1.000 0.506
Osteomyelitis of ankle AND/OR foot 11.770 0.001 1.000 1.000 0.000 1
Acute tubular necrosis 11.677 0.002 1.000 1.000 1.000
Chronic kidney disease stage 4 11.348 0.003 1.000 1.000 1.000
Gangrenous disorder 11.288 0.001 1.000 1.000 0.000 1
Deficiency of macronutrients 11.145 0.005 1.000 1.000 1.000
Secondary malignant tumour of lung 11.082 0.002 1.000 1.000 1.000
Infection from device, implant AND/OR graft 10.998 0.003 1.000 1.000 0.000 1
Acquired thrombocytopenia 10.841 0.002 1.000 1.000 1.000
ARF - Acute renal failure 10.841 0.012 1.000 1.000 1.000
Acute-on-chronic respiratory failure 10.812 0.001 1.000 1.000 1.000
Metastatic tumour of bone 10.758 0.002 1.000 1.000 1.000
Ulcer of heel 10.696 0.002 1.000 1.000 0.000 1
Chronic respiratory failure 10.633 0.001 1.000 1.000 1.000
Malignant neoplasm of liver 10.502 0.001 1.000 1.000 1.000
Acute on chronic systolic heart failure 10.471 0.001 1.000 1.000 1.000
secondary brain cancer 10.441 0.001 1.000 1.000 1.000
Pneumonitis due to inhalation of food 10.416 0.002 1.000 1.000 1.000
Ulcer of knee 10.392 0.001 1.000 1.000 0.000 1
RF - Renal failure 10.342 0.005 1.000 1.000 1.000
Acute respiratory failure 10.295 0.008 1.000 1.000 1.000
Secondary malignant neoplastic disease 10.265 0.002 1.000 1.000 1.000
Esophageal varices without bleeding 10.140 0.001 1.000 1.000 0.001 1
Obstruction of bile duct 10.090 0.001 1.000 1.000 1.000
Osteomyelitis 10.079 0.002 1.000 1.000 0.000 1
postoperative pulmonary insufficiency 10.058 0.002 1.000 1.000 1.000
Ulcer of lower limb 9.949 0.003 1.000 1.000 0.000 1
Metabolic encephalopathy 9.921 0.001 1.000 1.000 1.000
lung cancer 9.876 0.001 1.000 1.000 1.000
Dementia from another disease 9.849 0.002 1.000 1.000 1.000
Pulmonary oedema - acute 9.842 0.001 1.000 1.000 1.000
Drug-induced neutropenia 9.813 0.002 1.000 1.000 1.000
Hypertensive renal disease with renal failure 9.789 0.010 1.000 1.000 1.000
PAIN OF METASTATIC MALIGNANCY 9.772 0.001 1.000 1.000 1.000
throat cancer 9.568 0.003 1.000 1.000 1.000
Acidosis 9.564 0.005 1.000 1.000 1.000
Anaemia of chronic disease 9.555 0.004 1.000 1.000 1.000
Acute diastolic heart failure 9.406 0.001 1.000 1.000 1.000
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Chapter 3
Predicting Health Outcomes from
High Dimensional Longitudinal
Health Histories Using Relational
Random Forests
3.1 Introduction
With increasingly widespread use of Electronic Health Records (EHRs), predicting
health outcomes from high dimensional, longitudinal health histories is of central
importance to healthcare. The medical literature has formalized such prediction
problems in a few instances, and the resulting “risk calculators” attract widespread
use.
CHADS2 is one example of a risk calculator that is currently used in practice
to predict ischemic stroke in patients with atrial fibrillation (afib). The goal of
prediction with CHADS2 is to identify patients with sufficiently low risk of stroke
to be spared warfarin, an anticoagulant with well-known side effects that also re-
quires extensive monitoring. Like most widely used risk calculators, the statistical
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analysis underlying CHADS2 makes use of a small fraction of the available patient-
level information.
We use health insurance claims data from the Observational Medical Outcomes
Partnership (OMOP) to construct our own high dimensional risk calculators for
stroke in afib patients. (OMOP is a public private partnership that developed
methodological research experiments to study the performance of analysis meth-
ods in observational health data, both claims data and EHRs [1,2,3].) We first
apply standard machine learning approaches such as L1 regularized logistic re-
gression [4] and random forests [5,6] to naive mappings of patient histories into
simple (albeit high-dimensional) feature vectors containing coarse temporal infor-
mation about occurrences of health events. These methods demonstrate superior
predictive performance to CHADS2 in our database but fail to identify a sizable
population with very low risk of stroke.
We hypothesize that incorporating (potentially complex, high order) temporal
relations between health events may further improve predictive performance. The
challenge is to identify informative members of the vast set of such relations. To
this end, we adapt a predictive modeling method (referred to in the remainder as
Relational Random Forests, or RRF) originally developed in the context of speech
recognition [7]. RRF greedily constructs informative labeled graphs representing
temporal relations between multiple health events at the nodes of randomized
decision trees. We modify the existing algorithm so that the pool of candidate
temporal relations is determined by the data rather than specified (necessarily
arbitrarily, in our case) by the analyst.
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Many other researchers have considered the problem of developing predictive mod-
els from medical histories. Past efforts may be categorized according to their ap-
proach to variable selection. In the vast majority of cases, researchers generated a
small set of candidate covariates thought to be related to the outcome of interest
and employed traditional model selection algorithms such as stepwise regression
to choose among them. The CHADS2 score is a product of this approach, as are
other well known risk scores such as those arising from the Framingham Heart
Study.
Some researchers, like us, have taken a machine learning approach to variable
selection. That is, they define a very large set of features, few of which are a
priori likely to be related to the outcome, and employ algorithms such as regu-
larized regression or CART that automatically incorporate informative subsets of
the features into predictions. For example, [8] predicts hospital readmissions using
logistic regression with a modified forward variable selection algorithm to choose
features from the set of all indicator variables for any past occurrence of a medical
concept with an ICD-9 code. None of the many features used in [8], however,
conveys any information about time.
[9] did recently address the problem of incorporating temporal patterns from medi-
cal histories into predictive models. They consider a patient’s health history as the
superposition and concatenation of multiple pattern matrices. Each pattern ma-
trix specifies a rigid temporal relationship among health events that repeats over
time. They employ a matrix factorization algorithm (called OSC-NMF) to learn
101
the pattern matrices, which can then be used to construct features for predictive
models. RRFs are able to incorporate more flexible temporal relationships than
can be represented by pattern matrices, and the sample application of OSC-NMF
in [9] only involved 30 candidate health events compared to over 10,000 in our
application. We are curious about how OSC-NMF scales, and we hope to explore
this exciting approach more deeply in future work.
It is rare for a machine learning feature set to include temporal relationships
between large numbers of health events. The reason is that there are too many
such relationships for standard machine learning algorithms to identify informa-
tive subsets. The advantage of RRF is that it allows feature sets to effectively
include a wide class of temporal relationships.
3.2 Methods
Our data comprised detailed time-stamped insurance claims records of patient-
level health events (e.g. drugs prescribed, conditions diagnosed, procedures per-
formed, etc.) occurring over a span of several years from the MarketScan Multi-
State Medicaid database. In patients with atrial fibrillation and at least one year
of continuous observation period both preceding and following their first observed
afib diagnosis, we predicted the occurrence of stroke in the year following the index
afib diagnosis using multiple approaches. We considered patients who died to be
fully observed and thus only excluded patients who left the Medicaid program for
reasons other than death or who were diagnosed with afib less than a year before













Table 3.1: Estimated probability of stroke corresponding to each CHADS2 score
our dataset consisted of 12,581 patients, 1,850 of whom had strokes.
CHADS2 simply assigns point values for each of five conditions present in a health
history: one point each for congestive heart failure, hypertension, age > 75, or
diabetes, and two points for prior stroke. Each possible point total is associated
with a corresponding estimated probability of stroke in the next year. (See Ta-
ble 1.) CHADS2 was developed and calibrated using 2580 afib patients randomly
assigned to receive aspirin (and no warfarin). The included risk factors were cho-
sen because they were all found to be independently associated with stroke [10].
We calculated a CHADS2 score for each patient in our database and evaluated
predictive performance. On account of left censoring of variables that inform the
CHADS2 score, we expect that CHADS2 would perform better in a real world
setting than in our experiments. In particular, our ability to assess prior stroke is
limited to the patient observation period in the database. Similarly for congestive
heart failure, hypertension, and diabetes, we are relying on the appearance of di-
agnostic codes in the medical record during the observation period.
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To implement L1 regularized logistic regression and classical random forests, we
first encoded health histories into high dimensional binary feature vectors carrying
coarse temporal information. We created “time splits” spaced on a log scale at 0,
7, 55, 148, and 435 days before index date of afib diagnosis. For each health
event and for each time split, we created two binary predictors—one indicating
whether the health event era (e.g. the period of time during which a drug was
taken) extended before the time split and one indicating whether the health event
era extended after the time split. (See Figure 1 for an illustration.) Including all
drugs and conditions at all levels of a hierarchical taxonomy of health events [11],
our feature vectors contained over 100,000 binary predictors, as well as age and
gender.
Figure 3.1: An illustration of the encoding of health history information into a set
of binary predictors.
We fit standard L1-regularized logistic regression and random forest models to
these predictors. We used algorithms that exploited the sparseness of our predictor
matrix to cope with its high dimension. For regularized logistic regression we used
BBR software [12,13], and for classical random forests we used FEST software [14].
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The logistic regression model specifies that
log
(
P (Stroke | X)
1− P (Stroke | X)
)
= β′X
where X is a vector of predictors representing a patient history and β is a vector
of parameters to be estimated. In L1 regularized logistic regression, estimates β̂
are obtained as
argminβ − l (β) + λ ‖β‖1
where l(·) denotes the log likelihood function and λ is a tuning parameter. The penalty
term λ ‖β‖1 encourages sparse solutions with many coefficients in β set to zero and
allows regression models to be fit in scenarios with more predictors than observa-
tions. Larger values of λ lead to more sparsity, and its value is chosen through
cross validation to minimize an estimate of out of sample prediction error [4].
Random forests, as described in [5], are ensembles of decision trees. Each tree
is fit to a random subset of the observations (patients, in our application) and a
random subset of predictors. Predictions are calculated as the mean of the pre-
dictions of all the trees in the forest. Each tree’s prediction for a patient is the
proportion of strokes in the terminal node containing that patient. We chose to
consider √p potential predictors for each split, where p denotes the total number
of predictors, and we grew each tree to a maximum depth of 1000. We grew 1000
trees, at which point predictive performance appeared to have converged.
We hypothesized that incorporating certain complex temporal relationships among
multiple health events in the predictive models might lead to more accurate pre-
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dictions. The predictors we used for the standard machine learning approaches fail
to capture even simple relative temporal relationships of the sort “received drug A
then suffered condition B”. We can also imagine more specific relationships that
may be informative, such as “received drug A then suffered condition B within T
days” or “received drug A then suffered condition B all within T days of the index
date”. Such relationships among multiple variables are well described by labeled
graphs with health event types at the vertices and edges labeled to indicate tem-
poral relations between the vertices. Below is an example of a graph representing
a set of temporal relationships between health events that occurred in a patient
from our data set.
Figure 3.2: A graph representing temporal relations between multiple health events
in a health history from our database. Events at the tails of arrows occurred before
events at the heads. No information about the time between events or time from
events to index date is displayed in this particular graph.
To formalize, let V = {e1,. . . ,eH} be the set of all possible vertices (that is, the
set of all health events that occur in any patient). Then a labeled graph G is of
the form {(ei,1, ei,2, Ri), i = 1, . . . , |G|, ei,j ∈ V for j = 1, 2} where Ri specifies a
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temporal relationship between ei,1 and ei,2. We call each triplet (ei,1, ei,2, Ri) an
edge. We say a health history X satisfies an edge ei = (ei,1, ei,2, Ri) if ei,1 and
ei,2 occur in X and temporal relation Ri holds between them. We say a health
history X satisfies a graph G if it satisfies every edge in G. Let 1G (respectively,
1e) denote the random indicator variable that is equal to 1 if a patient’s health
history satisfies G (respectively, e) and 0 if not.
Our proposed approach grows random decision trees designed to produce infor-
mative labeled graphs at the nodes [7]. We call each tree grown in this way a
‘relational tree’. Each node of a relational tree is defined by two sets of edges,
which we will call I and E for “included” and “excluded”. Every patient in a
node satisfies each edge in I and none of the edges in E. The edges in I form a
labeled graph satisfied by all patients in the node. We grow decision trees by split-
ting nodes on variables of the form 1e for e an edge. Figure 3 depicts a sample tree.
To split a node, we first find a suitable edge e such that 1e is predictive of stroke
for the node’s population. Then we construct two child nodes—one comprising
the subpopulation that satisfies e and the other comprising the subpopulation that
does not. Algorithm 1 below describes how to split a node.
Algorithm 1 (Node splitting):
To split a node all of whose patients satisfy every edge in a set I and no edges in
a set E :
1. Let S denote the set of candidate edges to split on. Set S = {}
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2. While |S|< M for some pre-chosen M (we set M = 40):
(a) Select a random patient from the node population (we actually enforce
that an equal number of cases and non-cases are selected).
(b) Using algorithm 1A (below), select a random labeled edge s1 = (e1, e2, R)
satisfied by the patient’s history that is connected to I and not in E.
(To be connected to I , the new edge simply must contain a health event
that is included in at least one of the edges in I.)
(c) Create another labeled edge s2 = (e1, e2, R′) where e1 and e2 are as in
s1 and R’ is the temporal relation that e1 simply precedes e2.
(d) Set S = S ∪ {s1,s2}
3. For each edge s in S, calculate the node population’s conditional entropy
H(1Stroke|1s) ≡ −
∑
x∈{0,1},y∈{0,1}P (1s=x,1Stroke=y)log (P (1Stroke=y | 1s=x))
where P denotes the empirical probability measure for the node population
and 1Stroke is an indicator variable that is 1 if a patient had a stroke and 0
otherwise.
4. Let s* be the most informative edge in S, i.e. s*= argmaxsεS H(1Stroke|1s)
is the edge that maximizes conditional entropy. Create two new child nodes
N1 and N2 with N1 defined by (I1=I ∪ s*, E1=E) and N2 defined by (I2=I,
E2 = E ∪ s*).
Generating candidate labeled edges, which we do in Step 2 of Algorithm 1, posed
some difficulties. In their speech recognition application [7], Amit and Murua used
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domain knowledge to pre-specify a manageable set of possible edges and selected
candidate edges to split each node uniformly at random from this set. Their tem-
poral relations all took the form of non-overlapping time windows (e.g. event ei
occurs between T1 and T2 milliseconds before event ej).
In our application, there are on the order of 100 million possible pairs of health
events from which to choose the vertices for an edge. The probability of choosing
useful pairs uniformly at random is negligible. We also lacked the prior information
required to pre-specify appropriate temporal relations. The nature of our problem
suggests that the temporal relations ought to be at least somewhat flexible for
several reasons. First, there is a lot of presumably uninformative between-person
variation in the rate at which similar biological processes unfold. Second, there is
also presumably uninformative variation in the time from occurrence of a health
event to when it appears as an insurance claim and enters our database. There-
fore we do not expect extremely restrictive temporal relations (e.g. event ei occurs
exactly 10 days before event ej) to lead to good classifiers. But it is unclear how
permissive the temporal relations should be.
As a solution to these problems, we allowed the data to dictate candidate edge
generation. We set temporal relations to be random relaxations of precise relations
actually observed between health event pairs in the history of some patient in the
node being split. The process is described in detail in Algorithm 1A. As an ad-
ditional safeguard against overfitting, for each health event pair we also included
a candidate edge with the further relaxed relation that event 1 simply precedes
event 2 as described in step 2(c) of Algorithm 1.
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Algorithm 1A (Selecting a random edge from a patient in a node defined by
edge sets I and E, step 2b of Algorithm 1):
An edge will be of the form {event1,event2,(b,d)}, meaning event1 occurs between
0 and b days before event2and at most d days before index afib diagnosis.
1. Select a pair of health event occurrences e1 and e2 uniformly at random from
the patient’s health history such that at least one of the events is contained
in some edge in I and the two event occurrences are not connected by any
edge in E. Without loss of generality, let e1be the earlier of the two events.
Set e1 and e2 to be the vertices of the edge.
2. Let b’ = t1 – t2 where ti = the number of days before index that ei occurred.
Set b ∼ uniform(b′, T ) where T is the total number of days in the health
history.
3. Let d’ = t1. Set d ∼ uniform(d′, T )
Algorithm 1A generates random edges by beginning with an ’exact’ edge ob-
served in a patient history and then relaxing the temporal restriction by a random
amount. When growing a random forest, the goal is to find a good tradeoff be-
tween making each random tree a strong classifier and ensuring that the trees are
as uncorrelated with each other as possible [5,6,15]. Our scheme for generating
random edges is an intuitive attempt to find this tradeoff. Judgment and arbi-
trariness are still involved in selecting the general types of temporal relations we
search for. It would be possible to consider many other relations than those we
considered (for instance, the duration of time that two event eras overlap).
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We also note that we allowed the selection of edges containing the index afib
diagnosis as a vertex. Since every patient had an afib diagnosis on the last day of
their history, such edges contain no relational information. By allowing them, we
give RRF access to the sort of non-relational variables that could be included in
a standard random forest.
To grow an individual tree, we split nodes until a stopping rule is satisfied. There
are many reasonable options for stopping rules. For example, one can split nodes
until the gain in entropy or the size of the node population falls below a pre-
specified threshold. We continued to split nodes until their population fell below
100 patients.
Figure 3 depicts an example of a simple tree that might be grown using this
algorithm. Figure 4 depicts an actual tree that was grown.
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Figure 3.3: A hypothetical tree
As in [5,6,7], we grow many trees, splitting nodes as described in Algorithms 1 and
1A. The results we present are based on an ensemble of 1,000 trees. We determine
the predictive score for an out of sample patient by dropping that patient down
each tree in the ensemble and computing the pooled proportion of strokes in all
the terminal nodes to which that patient belongs. Standard variable importance
measures for conventional random forests [5] may be applied to identify the most
predictive health event patterns.
We evaluate out of sample predictive performance of all methods using 4 fold
cross validation. We consider summaries of predictive performance such as AUC
























































































































































Figure 3.4: One actual tree from a Relational Random Forest. In this tree, for
reasons of presentation, only ordering of events are depicted. At each terminal
node we list the included and excluded edges. For two terminal nodes we illustrate
the graph of temporal relations corresponding to the set of included edges. To the
right is a key of health events that appear in the tree.
3.3 Results
The three machine learning methods had similar out of sample (OOS) AUCs and
all outperformed CHADS2. (See Table 3.) They were also all well calibrated in
that empirical probability of stroke was an approximately non-decreasing function
of predictive score as illustrated in Figure 5. However, RRF was the only method
113
that was able to discriminate among low risk patients to identify a sizable popu-
lation of very low risk patients (see second column of Table 3).
The calibration plots (Figure 5) illustrate the shared strengths of the three ma-
chine learning methods and the advantage of RRF. In each calibration plot, each
point corresponds to a bin covering 2 percentiles of the model’s standardized pre-
dictive score outputs. Each point’s x-coordinate is the center of its bin, and the
y-coordinate is the proportion of patients whose OOS predictive score falls within
that bin who had strokes. Each calibration plot also includes a smoothed LOESS
line fit to the binned proportions.
The calibration plots show that all three methods discriminate well among high
risk patients. The nearly horizontal segment at the lower left of the random for-
est plot (top) indicates that the random forest does a poor job at discriminating
among low risk patients, estimating that they all have approximately .05 prob-
ability of stroke. The model is still well calibrated but does not reliably discern
gradations of risk below a certain threshold. The tightly clustered, football-shaped
collection of points in the lower left corner of the logistic regression plot (middle)
indicates that logistic regression does somewhat better at discriminating among
low risk patients as it has a higher slope than the corresponding region of the ran-
dom forest plot, but it still does not do well. In the corresponding area of the RRF
plot (bottom), we see that the cluster from the logistic regression plot has been
teased out and rises with a sharper slope as RRF does distinguish well between
low and very low risk patients. Below, we look at some quantitative consequences
of this visual comparison.
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[10] suggested that patients with less than .02 probability of stroke in the next
year in the absence of warfarin could reasonably be spared warfarin. In the stud-
ies [10] considered, this risk level corresponded to a CHADS2 score of 0. For each
model we implemented, we looked at the proportion of the population (N = 12,581
patients) the model could identify with empirical probability of stroke less than
p for various values of p including .02. To elaborate, for each model we found
the highest predictive score p̃ such that less than 100× p% of patients with OOS
predictive score lower than p̃ had strokes. If there was no value of p̃ satisfying this
condition, we set p̃ = −∞. We then considered the proportion of patients with
OOS predictive score less than p̃ to be the proportion of patients with empirical
risk of stroke less than p identified by the model. For example, 3.1% of patients
with a CHADS2 score of 0 had strokes, and 11% of patients had CHADS2 scores of
0. So CHADS2 identified 11% of the population with empirical risk of stroke less
than .031 but 0% of the population with empirical risk of stroke less than .02. As
illustrated in Table 3, only RRF identified a sizable proportion of the population
with empirical risk of stroke less than .02.
RRF also required far fewer trees to achieve its peak predictive performance than
did the standard random forest in our application. Figure 6 shows AUC and pro-
portion of low risk patients identified as functions of number of trees for both
methods. The computational gain that may be accrued by using fewer relational
trees may be offset by additional computational complexity involved in building
each relational tree, however. Evaluating whether a patient’s health history sat-
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RRF .783 .1 .04
Table 3.2: Summary of predictive performance of various methods at predicting
strokes. All machine learning methods had similar AUCs, but only RRF could
identify a sizable proportion of the population at very low risk of stroke.
isfies an edge is a somewhat more complex operation than simply looking up the
value of a pre-computed binary indicator variable. The worst case time complex-
ity of splitting one node in RRF is O((M + 2) × d ×N) where M is the number
of candidate edges, d is the maximum number of occurrences of an event in any
single patient’s health history, and N is the number of patients in the node [7].
The time complexity for splitting a node in a random forest with binary predic-
tors is O((M + 2)×N). So the node splitting complexity of RRF is greater than
standard random forests by a factor of d. In practice, d will often be quite small,
as it was in our application where most events occurred very infrequently. In some
applications, only the first occurrence of an event will be of interest and d will
be 1. Of course, the theoretical upper limit on d is the number of time points at
which each patient is observed.
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This application provides several heartening examples of predictive performance
improving with utilization of additional information. The machine learning meth-
ods that use data related to all health events perform markedly better than
CHADS2, which only takes a few researcher-selected health events as inputs. Of
the machine learning methods considered, RRF was able to incorporate the most
temporal information. The predictors that we constructed for logistic regression
and random forest did contain coarse temporal information about the occurrence
of individual health events, but only RRF could efficiently incorporate information
from the vast space of temporal interactions among multiple health events into its
predictions. For the task of predicting strokes from health histories considered
here, this led to potentially meaningful improvements over the more conventional
methods. More generally, RRF is a promising tool for predictive modeling in sit-
uations where the covariates comprise high dimensional time series.
A limitation of this study is the possibility that the probability estimates of all
methods we considered were biased by the exclusion of patients who left Medicaid
less than one year after their index afib diagnoses. Even if such bias was present,
the classification problem we considered was still well defined, though of unclear
clinical significance, and the predictive performance comparisons we presented are
valid for that problem. However, clinical interpretation of the probability esti-
mates would have to be relative to a somewhat unnatural population.
Though the emphasis of this paper is prediction, we briefly discuss some causal
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considerations that naturally arise when using predictive models calibrated on ob-
servational data to aid clinical decisions. We adopt Pearl’s do() operator [16] for
explication. A full decision analysis of whether to prescribe warfarin to a patient
with health history X would require the quantities P(stroke|X,do(no warfarin)),
P(stroke|X,do(warfarin)), P(bleed|X,do(no warfarin)), and
P(bleed|X,do(warfarin)). (Note that ’X’ can vary depending on the predictors
extracted from a health history.) CHADS2 aids clinical decision making by esti-
mating just the first of these quantities – P(stroke|X,do(no warfarin)). CHADS2
is able to directly target this quantity because it was calibrated to patients ran-
domly assigned not to take warfarin. Clinical considerations led experts to suggest
that values of P(stroke|X,do(no warfarin)) below .02 imply potential gains from
warfarin are so low as to not justify the risk. In the clinical trial population to
which CHADS2 was calibrated, a CHADS2 score of 0 corresponded to a value of
P(stroke|X,do(no warfarin)) that fell below this .02 threshold.
In our database of Medicaid patients, however, we saw that CHADS2 along with
logistic regression and random forests were all unable to identify many patients
with a marginal empirical probability of stroke P(stroke|X) < .02. The reasonable
assumption that warfarin never increases the probability of stroke, i.e. that the
quantity of interest P(stroke|X,do(no warfarin)) > P(stroke|X) for all X, would
imply that these methods are also unsuitable to identify patients from the Med-
icaid population with P(stroke|X,do(no warfarin)) < .02. Only RRF identified
patients with a sufficiently low observational P(stroke|X) that they may possibly
have prohibitively low causal P(stroke|X,do(no warfarin)) as well.
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(We should note that CHADS2’s relatively poor performance here may be due
to the limited time horizon of our data. Patients only receive CHADS2 points
for conditions related to insurance claims that occurred after they entered the
database. This could result in some high risk patients wrongly being given scores
of 0, thus inflating the proportion of strokes among those with scores of 0. Of
course, the other methods we implemented were also hampered by left censoring
of covariates.)
While we cannot reliably estimate the actual value of P(stroke|X,do(no warfarin)),
we consider the conditions under which the quantile of observational predictive
score P(stroke|X) at least corresponds to the quantile of P(stroke|X,do(no war-
farin)). We start by asking when it can be that
P(stroke|X1,do(no warfarin)) < P(stroke|X2,do(no warfarin)) but
P(stroke|X1) > P(stroke|X2) for health histories X1 and X2. Assuming that war-
farin always lowers the probability of stroke, this type of discordance can only
occur if patients with history X2 are more likely to take warfarin and/or warfarin
is more efficacious for patients with history X2. Whether patients with one pre-
dictive score are more likely to take warfarin than patients with another can be
checked empirically. In our data, for example, we find no evidence that patients
with very low RRF predictive scores were more likely to take warfarin than pa-
tients who had slightly higher predictive scores. Therefore, if the group of very
low risk patients we identified does not correspond to the patients with the lowest
P(stroke|X,do(no warfarin)), it is because warfarin was particularly efficacious in
this group. If clinicians judge that such a pattern of warfarin treatment effect het-
erogeneity is implausible or unlikely then they can take the ordering of patients by
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RRF predictive score as a proxy for the ordering of patients by P(stroke|X,do(no
warfarin)).
To summarize, CHADS2’s advantage of having been previously calibrated to a
randomized trial is largely moot for the Medicaid population we consider given
the failure of its calibration to randomized patients to generalize. Our predictive
model does not directly estimate the desired quantity because it was fit to ob-
servational data, but it is still potentially a useful tool for identifying Medicaid
patients who can be spared warfarin. Similar tools could be developed for other
populations in which CHADS2 fails to identify low risk patients. Despite stan-
dard limitations of observational data, RRF represents a promising approach for
making meaningful predictions from large-scale clinical databases.
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Chapter 4
A Note on the Effective Sample Size
in Importance Sampling
4.1 Introduction





h(x)f(x)dx = Ef [h(X)],
where X is the support of the random variable X, h(x) ≥ 0, and f(·) is a prob-
ability density function. Importance sampling draws x(1), . . . , x(m) from an easy-





w(1)h(x(1)) + . . .+ w(m)h(x(m))
}
where w(j) = f(x(j))/g(x(j)), j = 1, . . . ,m. Normalization of the weights is com-
mon and sidesteps the computation of normalizing constants in f and g. A good
candidate for g(·) is one that is close to the shape of f(x). However, so long as
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the support of g(·) includes the support of f(·), essentially any distribution can
be used. The literature includes an array of specialized importance sampling algo-
rithms including sequential imputation (Kong et al., 1994), adaptive importance
sampling (Oh and Berger, 1992), and annealed importance sampling (Neal, 2001),
to name a few.
While the variance of µ̃ can in fact be smaller than that of an estimate obtained
using independent samples from f(·) (Liu, 2001, p.24), it is more typically the case
that importance sampling serves as a less precise substitute when f(·) is hard-to-
sample. The variance of µ̃ is sometimes large even for large m.
As a way of quantifying the difference in precision between estimates arising
from different sampling methods, several authors have discussed rules of thumb to
approximate the so-called “effective sample size” (ESS). The ESS of m importance
sampling draws from g(·) to estimate µ is defined to be the number of independent
draws directly from f(·) that would be required to obtain an estimate with the
same variance. The standard formula for the approximate ESS is:
ESS(m) ≈ m
1 + Varg [w(x)]
. (4.1)
The first explicit reference to the formula seems to be Kong et al. (1984), and it
is apparently in widespread use.
Liu (1996) and especially Liu (2001) sketch a derivation of (1). Here we pro-
vide a detailed derivation and analysis of the approximation. Kong (1994) notes
that the approximation is somewhat crude but still finds it appealing because it
does not depend on h(·). Liu (2001) comments that one of its omitted terms
“is not necessarily small.” We show with some simple numerical examples that
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Liu is indeed correct and that the formula can be misleading. We also propose
a new approximation for the ESS and demonstrate its superior accuracy in some
examples.
4.2 An Analysis of the Effective Sample Size
Formula
4.2.1 Derivation
Importance sampling first generates independent samples x(1), . . . , x(m) from an
















where w(x(j)) = f(x(j))/g(x(j)), j = 1, . . . ,m.




(j)) where the y(j) are
i.i.d. draws from f(·). Then the ESS is, by definition, the value of m′ for which
V arf (ˆ̂µ) = V arg(µ̂). Because V arf (ˆ̂µ) = 1m′V arf (h(y)), y ∼ f , we have:




Consider first the denominator V arg(µ̂) in (4.3). We will use Cramer’s Theorem
(Sen and Singer, 1993) to approximate this quantity:
Cramer’s Theorem Let {Tm} be a sequence of random q-vectors with common
mean vector θ, r a positive integer, and π : Rq → R such that the following three
conditions hold :
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(i) |π (Tm) | ≤ cmp where c and p are finite constants.
(ii) there exists k > r (p+ 1) andm0 = m0 (k) such that for allm ≥ m0, E[
√
m (Tmj − θj)]2k <




π(x) is continuous and bounded in some neighborhood of θ,i, j =
1, . . . , q
Then,
E{π(Tm)− π(θ)}r = E{
∑q
j=1 π







Let Z = h(x)w(x),W = w(x), H = h(x) and let Z andW be the corresponding
sample averages, so that µ̂ = Z
W




. Then θ := (µ, 1) =
Eg (Tm). Define π (a, b) = ab so that π (Tm) =
Z
W
= µ̂, π (θ) = µ, and π′ (θ) =
(1,−µ). Plugging Tm, θ, and π into Cramer’s Theorem twice (once with r = 2 and




− µ)2 = Eg[(Z − µ)− µ(W − 1)]2 +O(m−
3







− µ) = Eg(Z − µW ) +O(m−1) = µ− µ+O(m−1) = O(m−1).
So:
V arg(µ̂) = V arg(
Z
W
) = V arg(
Z
W
− µ) = Eg( ZW − µ)
2 − [Eg( ZW − µ)]
2
= Eg(Z − µW )2 +O(m−
3
2 )−O(m−2) = V arg(Z − µW ) +O(m−
3
2 )
≈ V arg(Z − µW ) =
1
m
[V arg(Z) + µ
2V arg(W )− 2µCovg(Z,W )] (4.4)
So far, we have ignored one remainder term,
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R1 = V arg(
Z
W
)− V arg{Z − µW} = O(m−
3
2 ). (4.5)
To reproduce Kong’s formula, first note that
Covg(Z,W ) = Eg(HW
2)−µ = Ef (HW )−µ = Covf (H,W )+µEf (W )−µ (4.6)
Also,
V arg(Z) = Eg(Z
2)− [Eg(Z)]2 = Eg(H2W 2)− µ2 = Ef (H2W )− µ2
= Ef (H
2)Ef (W ) + 2µEf (HW )− 2µ2Ef (W ) + Ef (H2W )− Ef (H2)Ef (W ) + µ2Ef (W )
−µ2Ef (W )− 2µEf (HW ) + 2µ2Ef (W )− µ2
= Ef (H
2)Ef (W ) + 2µ[Ef (HW )− µEf (W )] + Ef{[W − Ef (W )](H2 − 2µH + µ2)} − µ2
= [Ef (H)]
2Ef (W ) + V arf (H)Ef (W ) + 2µCovf (H,W ) + Ef{[W − Ef (W )](H − µ)2} − µ2
(4.7)




{[Ef (H)]2Ef (W ) + V arf (H)Ef (W ) + 2µCovf (H,W )




{µ2Eg(W 2) + µ2Eg(W 2)− µ2[Eg(W )]2 − 2µ2Ef (W ) + V arf (H)Ef (W ) + µ2




V arf (H)[V arg(W ) + 1] +
1
m
Ef{[W − Ef (W )](H − µ)2}
≈ 1
m
V arf (H)[V arg(W ) + 1]. (4.8)
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Ef{[W − Ef (W )](H − µ)2}, (4.9)
to obtain V arg(µ̂) = 1mV arf (H)[V arg(W ) + 1] +R1 +R2.
Plugging this approximation into the expression for the true ESS (3), we get
Kong’s approximation:




V arg(W ) + 1
.
4.3 Numerical Study
To assess the performance of the approximation, we need to evaluate the true ESS
(V arf (H)
V arg(µ̂)
). In the following examples, f(·) is simple enough to calculate V arf (H)
exactly. We estimated V arg(µ̂) by taking the sample variance of µ̂′s generated
from many independent simulations.
4.3.1 Comparison of Formula with Truth for Some Simple
Examples
Tables 4.1, 4.2, and 4.3 present simple univariate examples illustrating the (in)accuracy
of Kong’s formula. Table 4.1 considers two examples that simulate from an ex-
ponential distribution (specifically an exponential with parameter 1) when the
target distribution is gamma. In one case (gamma(2,0)), the approximation over-
estimates the true ESS while in the other case (gamma(3,4)), the approximation
underestimates the true ESS. In both cases the approximation does not appear to
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f(x) ∼ Gamma(a, b), g(x) ∼ Exp(1)
a=2 b=0.8 a=3 b=4
m True Formula True Formula
100 8 26 127 68
500 42 132 627 342
1000 78 264 1224 684
2000 142 527 2616 1368
5000 311 1318 6405 3419
8000 516 2109 9420 5471
10000 627 2637 12403 6839
20000 1217 5373 24542 13678
50000 2739 13184 58974 34194
Table 4.1: Two examples comparing the true and approximate effective sample
size for estimation of a gamma mean using an exponential as a trial distribution.
improve as the number of draws m increases. The two examples in Table 4.2 use
a uniform distribution on zero to one as the trial distribution with a beta distri-
bution as the target. In both cases, the approximation underestimates the true
ESS. Finally, Table 4.3 shows two examples where both the trial distribution and
the target distribution are normal. In one case the approximation underestimates
the true ESS while in the other case it overestimates.
These tables clearly demonstrate that the approximate ESS can be quite far
from the true ESS in either direction.
4.3.2 Remainders
We will show that disparities which persist even for large samples, e.g. in the














f(x) ∼ Beta(a, b), g(x) ∼ Unif(0, 1)
a=2 b=1 a=3 b=2
m True Formula True Formula
100 95 75 108 73
500 494 375 544 365
1000 985 750 1095 729
2000 2000 1500 2205 1458
5000 4745 3750 5444 3646
8000 7208 6000 8775 5833
10000 9831 7500 10923 7292
20000 18951 15000 22037 14583
50000 41572 37500 54865 36458
Table 4.2: Two examples comparing the true and approximate effective sample
size for estimation of a beta mean using a uniform as a trial distribution.
f(x) ∼ N(a, b2), g(x) ∼ N(0, 1)
a=1 b=1 a=0.5 b=0.8
m True Formula True Formula
100 22 37 95 78
500 93 184 463 388
1000 232 368 939 776
2000 369 736 1869 1553
5000 941 1839 4693 3881
8000 1482 2943 7389 6210
10000 1942 3679 9572 7763
20000 3930 7358 21037 15526
50000 9263 18394 49210 38815
Table 4.3: Two examples comparing the true and approximate effective sample size
for estimation of a normal mean using a standard normal as a trial distribution.
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Hence, for (1) to be a good approximation, R1 and R2 must both converge to 0
faster than O( 1
m
).
We saw in the derivation of the approximation in Section 2.1 that, if the con-




). Condition (i) is easily
satisfied if h(·) is bounded, which for any practical purpose it could be, even if
by an extremely large number. Condition (ii) follows from Hoeffding’s Inequal-
ity, which implies that the tail probabilities of
√
m(Zm − µ) and
√
m(Wm − 1)








which is continuous in a neighborhood of θ = (µ, 1). Hence, as all the condi-
tions of Cramer’s Theorem are satisfied, mR1 should be small for large enough
m. mR2 = Ef [(W − Ef (W ))(H − µ2)], on the other hand, is constant and not
necessarily small compared to V arf (H)[V arg(W )+1]. In the example on the right
half of Table 1, for instance, V arf (H)[V arg(W ) + 1] = 0.27 and mR2 = −0.24.
4.4 An Adjusted Formula
As a remedy, we propose simply including R2 in the approximation, resulting in
the formula
ESS ≈ m




We can’t evaluate R2
V arf (H)
exactly in most cases, so we estimate it using importance
sampling. This can be done without generating any additional samples beyond
those already used for the primary estimation problem. We compared the per-
formance of our adjusted approximation to the standard approximation in several
examples for which we could determine the true ESS.
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4.4.1 Numerical Study
Tables 4.4, 4,5, and 4.6 repeat the examples of Tables 4.1, 4.2, and 4.3, but now
including the estimated ESS using the adjusted formula. In the tables, the “True
ESS” column shows the actual ESS. “Kong’s Formula” uses (1) to approximate
the ESS. “Adjusted (exact)” uses the adjusted formula with an exact computation
of R2. “Adjusted (simulated)” approximates R2 using the importance sampling
draws. While we of course purposely selected examples where Kong’s Formula
fails, the examples that appear were the first and only considered for our modified
estimator.
Note that even when importance sampling is inefficient, the adjusted approxi-
mation performs better than the standard formula.
f(x) ∼ Gamma(a = 3, b = 4), g(x) ∼ Exp(1)
m True Kong’s Adjusted Adjusted Adjusted Adjusted
ESS Formula (exact) (sim median) (sim .05Q) (sim .95Q)
100 121 68 124 123 114 135
500 583 342 621 620 598 644
1000 1268 684 1241 1240 1208 1275
2000 2615 1368 2482 2481 2436 2529
5000 6271 3419 6206 6204 6132 6279
8000 10595 5471 9929 9928 9835 10025
10000 12938 6839 12411 12410 12307 12520
20000 24646 13678 24822 24825 24671 24970
50000 63842 34194 62056 62052 61823 62286
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f(x) ∼ Gamma(a = 2, b = .8), g(x) ∼ Exp(1)
m True Kong’s Adjusted Adjusted Adjusted Adjusted
ESS Formula (exact) (sim median) (sim .05Q) (sim .95Q)
100 8 26 6 21 7 43
500 42 132 28 67 22 123
1000 78 264 57 114 39 197
2000 142 527 113 199 72 330
5000 311 1318 283 421 173 670
8000 516 2109 452 653 227 986
10000 627 2637 565 806 353 1169
20000 1217 5373 1130 1500 662 2077
50000 2739 13184 2825 3409 1792 4548
Table 4.4: Two examples comparing the true and approximate effective sample
size for estimation of a gamma mean using an exponential as a trial distribution.
f(x) ∼ Beta(a = 2, b = 1), g(x) ∼ Unif(0, 1)
m True Kong’s Adjusted Adjusted Adjusted Adjusted
ESS Formula (exact) (sim median) (sim .05Q) (sim .95Q)
100 95 75 94 94 86 103
500 494 375 469 468 451 487
1000 985 750 938 937 911 962
2000 2000 1500 1875 1876 1839 1915
5000 4745 3750 4688 4686 4631 4742
8000 7208 6000 7500 7500 7428 7580
10000 9831 7500 9375 9378 9297 9454
20000 18951 15000 18750 18744 18626 18866
50000 41572 37500 46875 46872 46697 47065
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f(x) ∼ Beta(a = 3, b = 2), g(x) ∼ Unif(0, 1)
m True Kong’s Adjusted Adjusted Adjusted Adjusted
ESS Formula (exact) (sim median) (sim .05Q) (sim .95Q)
100 111 73 109 109 102 117
500 553 365 547 547 532 564
1000 1095 729 1094 1093 1071 1118
2000 2106 1458 2188 2187 2156 2217
5000 5046 3646 5469 5469 5414 5518
8000 8974 5833 8750 8751 8685 8811
10000 10794 7292 10938 10939 10866 11007
20000 22656 14583 21875 21876 21777 21976
50000 55322 36458 54688 54680 54532 54838
Table 4.5: Two examples comparing the true and approximate effective sample
size for estimation of a beta mean using a uniform as a trial distribution.
f(x) ∼ N(1, 1), g(x) ∼ N(0, 1)
m True Kong’s Adjusted Adjusted Adjusted Adjusted
ESS Formula (exact) (sim median) (sim .05Q) (sim .95Q)
100 21 37 16 35 14 64
500 97 184 80 128 54 207
1000 198 368 160 240 111 358
2000 363 736 320 440 227 630
5000 924 1839 800 1032 609 1354
8000 1438 2943 1281 1607 1044 2020
10000 1755 3679 1601 1991 1377 2447
20000 3534 7358 3202 3881 2768 4664
50000 9277 18394 8005 9512 7536 10887
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f(x) ∼ N(0.5, 0.82), g(x) ∼ N(0, 1)
m True Kong’s Adjusted Adjusted Adjusted Adjusted
ESS Formula (exact) (sim median) (sim .05Q) (sim .95Q)
100 95 78 118 94 88 102
500 463 388 592 472 456 490
1000 939 776 1184 945 922 970
2000 1869 1553 2369 1889 1859 1924
5000 4693 3881 5922 4722 4670 4775
8000 7389 6210 9476 7555 7490 7621
10000 9572 7763 11845 9445 9373 9519
20000 21037 15526 23690 18888 18782 18990
50000 49210 38815 59225 47224 47069 47395
Table 4.6: Two examples comparing the true and approximate effective sample size
for estimation of a normal mean using a standard normal as a trial distribution.
4.5 Conclusion
The ESS can be a useful tool for understanding the precision of estimates obtained
through importance sampling. We have demonstrated that the standard approxi-
mation can be quite inaccurate, even for large numbers of draws, because it ignores
a remainder term that is constant and not necessarily small. By simply estimating
the remainder term, we can arrive at a better approximation. In situations where
information conveyed by the ESS is consequential, it may be worth the additional
computational cost to generate a more accurate approximation.
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